Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
10-7-2014 12:00 AM

Regulation of IGFBP-1 Phosphorylation in Hypoxia Via mTOR
Signaling
Ian Damerill, The University of Western Ontario
Supervisor: Dr. Madhulika Gupta, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Master of Science degree in
Biochemistry
© Ian Damerill 2014

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Biochemistry Commons

Recommended Citation
Damerill, Ian, "Regulation of IGFBP-1 Phosphorylation in Hypoxia Via mTOR Signaling" (2014). Electronic
Thesis and Dissertation Repository. 2473.
https://ir.lib.uwo.ca/etd/2473

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

REGULATION OF IGFBP-1 PHOSPHORYLATION IN HYPOXIA VIA MTOR
SIGNALING
(Thesis format: Monograph)

by

Ian Damerill

Graduate Program in Biochemistry

A thesis submitted in partial fulfillment
of the requirements for the degree of
Master of Science

The School of Graduate and Postdoctoral Studies
The University of Western Ontario
London, Ontario, Canada

© Ian Damerill, 2014

Abstract
This study provides novel evidence for a role of fetal liver mTOR signaling in regulating
IGF-I bioavailability by modulating IGFBP-1 phosphorylation due to hypoxia – a key factor
in the development of reduced fetal growth in utero. I utilized HepG2 cells in vitro and
demonstrated a link

between mTOR

inhibition and hypoxia-induced

IGFBP-1

phosphorylation. Using a biological assay for IGF-I receptor autophosphorylation, my data
demonstrated a functional significance for hypoxia-induced IGFBP-1 phosphorylation in
reducing IGF-I bioactivity in vitro. Further, I have implicated a mechanistic link to increased
CK2 activity within this regulation. I demonstrate that mTOR inhibition induced IGFBP-1
phosphorylation, which was not further enhanced by hypoxia, and that mTOR activation
prevented hypoxia-induced IGFBP-1 phosphorylation. Together, my work has identified a
new mechanism involving mTOR inhibition during hypoxia by which IGFBP-1
phosphorylation, and thus IGF-I bioavailability, is regulated, and also implicate increased
CK2 activity as an intermediate process in this mechanism.
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1.0 Introduction
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Regulation of fetal growth

Fetal growth is determined by the maternal and fetal genomes, as well as the placenta.
However, fetal growth is responsive to and dependent on environmental factors, of which
adequate supply of oxygen and nutrients to the fetus through the placenta are the most
critical (1). The maternal genome influences growth of the fetus, although its contribution
is difficult to quantify as the fetal genome is half shared with the mother. In early fetal
life, the maternal and fetal genomes contribute largely to the regulation of growth.
However nutritional, hormonal, and environmental factors become increasingly
determining of growth as gestation progresses (2). It is becoming increasingly evident
that the maternal and uteroplacental environment are the largest determinants of fetal
growth (2-4). Varying environmental conditions, namely the adequacy in the supply of
oxygen (5) and nutrients (4), largely influence the development of the fetus. The result of
inadequate supplies of nutrients or oxygen to the fetus, which can occur as a result of
many different factors including poor placental function, is markedly reduced fetal
growth. This can have long term physiological consequences on the affected human
which persist throughout life (6-8).

1.1 Fetal growth restriction
Fetal growth restriction (FGR) refers to poor development of the fetus, and is clinically
defined as fetuses whose weight is below the 10th percentile for gestational age (9). FGR
is a pregnancy complication associated with poor outcomes including an increased risk of
perinatal hypoxia (10) and neonatal demise (11). FGR infants are susceptible increased
rates of prenatal and neonatal mortality and neonatal morbidities (11). Infants who
survive gestation have an increased chance of neurodevelopmental disorders, as well as
developing cardiovascular disease, obesity, and diabetes in childhood and as adults (12).
Inadequate supplies of nutrients to the fetus, leading to an abnormal intrauterine milieu,
have long lasting effects on the fetal and postnatal development patterns. This
phenomenon can lead to a limitation in the supply of hormones and substrates necessary
for fetal development and can be a precursor to the development of type-2 diabetes (13-
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15). These limitations can permanently affect development by altering gene expression,
particularly in certain cell types such as adipocytes, myocytes, pancreatic beta cells, and
hepatocytes (13). Epidemiological changes in gene expression regulating growth and
management of energy have been noted in various historical cases (16-19). Indeed, it is
well established that fetal development and responses to environmental stimuli cause
changes to expression patterns of the fetal genome, which can lead to permanent
physiological changes which are retained post-natally. For example, restrictions such as
low protein in the maternal diet during pregnancy have been shown to result in lifelong
elevation in blood pressure in rats (20-23). These findings demonstrate that fetal growth
is largely determined by environmental factors, and that a proper fetal environment is
essential for a correct development. Although the etiology of FGR is multifactorial, in
most instances fetal growth is constrained by abnormal placental function, which results
in inadequate maternal supply of oxygen and/or nutrients. The molecular mechanisms
that regulate FGR caused by hypoxia and nutrient deprivation are not well understood.

1.2 Regulation of fetal growth in hypoxia
Along with nutrient restriction, inadequate oxygen supplies to the fetus leads to growth
restriction. In fact, decreased placental perfusion and fetal hypoxia are the leading causes
of FGR (24). Pregnancies that are complicated by reduced maternal oxygen-carrying
capabilities, as well as fetal anemia and hypoxia, result in severe growth restriction and
FGR (5), implicating a critical importance of an adequate oxygen supply during
gestation. Indeed, it has been shown through the study of chicken embryos that hypoxic
conditions alone are sufficient to cause FGR (25). The fetal development of numerous
tissues and organ systems are affected by fetal hypoxia. Studies have shown a correlation
between fetal hypoxia and reduced hippocampal volume, as well as an increased chance
of developing schizophrenia (26, 27). In fact, there is a growing body of evidence
implicating fetal hypoxia as a predictor of early-onset schizophrenia (28-30). Further, it is
known that fetal hypoxia results in a reduced volume of fetal blood (31). Cellular damage
to the central nervous system has also been associated with fetal hypoxia (32). Fetal
hypoxia also effects growth on a global scale. Infants born at high altitude are of lower
birth weight (33, 34), reflecting the responsiveness of fetal growth to reduced oxygen
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availability. Numerous neurological pathologies have been associated with fetal hypoxia,
including cerebral palsy, ADHD, and epilepsy (35-40). This strongly suggests that
healthy levels of oxygen are critical for proper neurological development. This may also
explain the association between reduced oxygen and smaller birth weight, as reductions
in growth occur asymmetrically with retardations in head and brain development
happening last (39). Although it is known that fetal hypoxia restricts growth, the
molecular mechanisms linking hypoxia to restricted fetal growth are not well understood.
Evidence has been put forth that suggest that hypoxia influences fetal growth via the
insulin-like growth factor (IGF) system – the predominant growth factor system which
regulates and promotes fetal growth (41).

1.3 Insulin-like growth factor system and the regulation of
fetal growth
The insulin-like growth factor system is a family of ligands, receptors, and binding
proteins which play a crucial role in fetal and post-natal development by promoting
mitogenic actions within the cell. The system involves two IGF ligands, two IGF
receptors, and six IGF binding proteins which collectively function to regulate growth in
a temporal, regional, and environment-responsive manner. The insulin-like growth
factors (IGF-I and II) are growth peptides which share a high sequence similarity with
insulin (42, 43). They share a high structural homology with proinsulin (42, 43), and have
been shown to be involved in the promotion of cell proliferation and inhibition of
apoptotic pathways (44-47). Concentrations of IGF-I and II in fetal circulation are
reduced by undernutrition and a deficiency of nutritionally sensitive hormones, such as
insulin (48, 49). Studies by Baker et al. have shown that targeting of the Igf-1 gene for
knockout in mice results in a 40% reduction in body weight in comparison to wild-type
littermates (50). Interestingly, a decrease in placental size did not occur as a result of Igf1 knockout. Postnatal growth of these mice was also affected, with both retarded and
delayed bone growth as well as infertility occurring (50).
IGF-I is intimately involved in the regulation of postnatal organ and neural development.
IGF-I signaling is involved in the regulation of neurogenesis, synaptogenesis,
myelination, and dendritic branching (51-53). It has further been linked with
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neuroprotection following brain damage, likely through its antiapoptotic effects (54, 55).
Not surprisingly then, increased IGF-I in serum has been shown to correlate with higher
IQ in children aged 5, 7, and 8 (56). The utilization of IGF-I in development ranges from
gestation to growth in late puberty. Indeed, a correlation has been established between
serum levels of IGF-I and the connection between short height and reduced hearing
capabilities. This effect was most prominent in children aged 3-5, as well as age 18 (57),
demonstrating the ongoing necessity for maintained IGF-I serum levels throughout
development.

1.4 Insulin-like growth factors (I and II) in regulation of fetal
growth
Both IGF-I and IGF-II have critical roles in the gestational development of humans. IGFII has a prominent role in regulating embryonic growth in early gestation (58). In
embryonic and early fetal development, Igf2 gene expression is high in numerous tissues,
and IGF-II levels are high in fetal serum (59). It is believed that embryonic and early fetal
growth are regulated mainly in an autocrine manner, whereas growth in the second half
of gestation is strongly regulated in an endocrine manner (58). IGF-II functions by
binding to IGF-I receptor (IGF-1R) in order to promote its mitogenic effects on cells
(58). IGF-II also binds to IGF-2 receptor (IGF-IIR), although interestingly the function of
this receptor is to sequester bioavailable IGF-II from circulation and thus attenuate the
effects of IGF-II (60). Both IGF-I and IGF-II contribute to fetal growth, with deletions of
the Igf1 or Igf2 genes resulting in markedly reduced fetal growth (50). Conversely,
overexpression of the Igf2 gene results in fetal overgrowth (61, 62).
During mid gestation, the emphasis on growth factor regulation by IGFs gradually
switches from an IGF-II bias to an IGF-I bias, where IGF-I-mediated effects are
dominant in mid and late gestation as well as in postnatal life (58). Interestingly,
concentrations of serum IGF-II are higher than IGF-I in late gestation (48). However,
studies have shown no association between serum IGF-II concentrations and fetal weight
during late gestation. Conversely, umbilical cord and fetal IGF-I serum concentrations
have been shown to be correlated with fetal weight (63, 64). This is supported by the fact
that fetuses displaying FGR contain reduced concentrations of IGF-I both in utero and at
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birth (65, 66), whereas neonates who are born large for gestational age contain increased
IGF-I concentrations (67).

IGF-I is mainly produced and secreted by the fetal and post-natal liver and functions in
an endocrine manner to promote growth globally (5). It also functions in a paracrine and
autocrine manner, functioning to promote growth of the liver. Human growth hormone
(GH) also plays a critical role in the development of humans (5). Both IGF-I and GH are
utilized in post-natal development, where IGF-I mediates growth-promoting effects of
GH (68, 69). IGF-I is critical in prenatal development, whereas GH has not demonstrated
a major role during this period, as GH receptors are only expressed in low levels in the
fetus (49, 70). Infants with either defects in their GH-receptor gene, or a congenital GH
deficiency, only display a mild attenuation in growth size at birth (71). Conversely,
defective Igf1 gene expression, as seen through mouse knockout studies, demonstrate
severe growth restriction at the embryonic stage as well as at birth (50). IGF-I functions
by binding to the IGF-I receptor (IGF-1R) but not IGF-IIR (72), which subsequently
stimulates numerous signaling cascades including Rac, IRS-1, and Ras/Raf activation in
order to promote cellular growth, proliferation, migration, and the inhibition of apoptosis
(73). Together, these data demonstrate the importance of IGF-I on the growth and
development of the fetus. As such, the IGF-I system and IGF-I bioavailability need to be
intimately regulated in order to respond to fetal environmental changes. This is done
through the actions of insulin-like growth factor binding proteins (IGFBPs).

1.5 Insulin-like growth factor binding proteins: an important
component of the IGF system
Insulin-like growth factor binding proteins are also produced and secreted into tissues and
circulation. Six IGFBPs exist (IGFBP-1 to -6) which bind to IGF-I and IGF-II with high
affinity. They function to stabilize IGF-I and IGF-II, prolonging their half lives and either
promoting or attenuating their biological activity with IGF receptors (74, 75). IGFBPs are
either produced and secreted by the liver into circulation or secreted in specific cell types
to function in a paracrine manner where they bind to IGFs. Once secreted, they can
perform various functions such as direct the IGF:IGFBP complexes to target tissues (76)

6

or prevent them from leaving circulation (77). IGFBPs are a well conserved family of
proteins. The IGFBP genes have a shared structural organization, with four conserved
exons having been established (78). These exons range in size from 5 kb in IGFBP-1, to
over 30 kb in IGFBP-2 and IGFBP-5 (78). It has been postulated that the IGFBP gene
family may be part of a larger gene superfamily, as exon 1 of the IGFBP gene family is
shared by other genes (79, 80). IGFBPs are secreted into circulation or tissue
extracellular matrix. IGFBP precursor proteins all contain signal peptides for secretion
which range between 20-39 amino acids in length and as such, the mature IGFBP
peptides are found extracellularly (81). Structurally, IGFBPs are all highly conserved and
share similar tertiary patterns. The IGFBPs have similar molecular weights, ranging from
approximately 24 to 50 kDa, or 216 to 289 amino acids (82).

1.6 Insulin-like growth factor binding protein structure and
IGF binding
All IGFBPs contain a structured N terminal and C terminal domain, with a less structured
flexible linker domain. The conserved N terminal domain contains six disulfide bonds
due to a GCGCC motif (83). This is present in IGFBP-1 to IGFBP-5. IGFBP-6, however,
lacks the last two cysteines of this motif and only contains five disulfide bonds as a result
(84). There are differences in the organization of these disulfide bonds between IGFBPs.
Despite these differences, however, structural analysis has determined that the disulfide
bonds in the N terminal domain of IGFBPs are all paired within the domain (83). This
provides further evidence of a conserved flexibility within the IGFBPs due to the
unstructured linker region being unhindered by disulfide bonds. IGFs bind to the N
terminal domain of IGFBPs. This was initially predicted via nuclear magnetic resonance
(NMR) imaging (85), and later confirmed using mutagenic studies (86-88). IGFBP-3 and
IGFBP-5, for example, were characterized to bind IGF-I on the N terminus via recent
mutagenic studies (86). Similarly, a site-directed mutagenesis study on IGFBP-1 revealed
that a 60 amino acid deletion in the N terminal of IGFBP-1 abolished IGF binding. In the
same study, it was found that a specific point mutation of Cys38 to tyrosine was able to
prevent IGF binding, demonstrating the necessity of the N terminal of IGFBPs in the
binding of IGFs (89).
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The C terminal domains of IGFBPs are also conserved in structure, in which all IGFBPs
are relatively cysteine rich and contain three disulfide bonds (84, 90). Like the N
terminus, the disulfide bonds within the C terminus are contained within the C terminus
(91). It is known that the C terminal domains of IGFBP-1, -2, -4, and -6 all adopt a
thyroglobulin type 1 fold and also possess flexible regions (83). Binding to IGFs also
occurs in this region. Brinkman et al. showed that a 20 amino acid deletion in the C
terminus of IGFBP-1 as well as a Cys226 mutation both prevented IGF-I binding,
suggesting that the C terminus is involved in binding of IGF-I in IGFBP-1 (92).
The linker, or central domain of IGFBPs, is unstructured and flexible. No conservation in
structure has been identified between IGFBPs in this region (72). The linker region
contains sites for post-translational modification. Sites for proteolytic cleavage have been
identified within the linker region, as well as potential phosphoacceptor sites on all
IGFBPs (93). Further, phosphorylation in this region has been established on IGFBP-1,
IGFBP-3, and IGFBP-5 (93), although direct binding of IGFs to the linker region has not
been demonstrated.

1.7 Insulin-like growth factor binding proteins and IGFmediated growth
Each IGFBP performs a unique function, or set of functions, within humans. IGFBP-2
has been shown to demonstrate inhibitory effects on IGF actions. The inhibitory effects
of IGFBP-2 seem to be greater on IGF-II, as IGFBP-2 binds to IGF-II with higher affinity
than IGF-I (60). IGFBP-2 is present in fetal development. In humans, IGFBP-2 levels
increase in the amniotic fluid at 9-12 weeks of gestation (94), suggesting that IGFBP-2
plays a role in the regulation of early fetal development. As IGF-II actions are potent in
early fetal development, IGFBP-2 may be increased in a temporal manner to regulate
these actions. IGF-II is important for embryonic development, however growth at this
stage is regulated in an autocrine rather than an endocrine manner (58). It is possible that
IGFBP-2 levels rise in a temporal manner to regulate IGF-II-mediated growth as growth
becomes more dependent on endocrine-related regulation. Interestingly, IGFBP-2 mRNA
levels were found to be 8 times and 25 times higher than IGFBP-1 in rat kidney and brain
tissues, respectively, in fetal rats. This suggests that throughout fetal development,
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IGFBP-2 may function in a tissue-specific biased manner (95). The bias towards IGF-Imediated growth, which occurs during the period in pregnancy where environmental
factors become increasingly determinant on the influence over fetal growth (2, 58),
makes the study of IGFBP-1 a more suitable candidate for study in assessing the effects
of fetal hypoxia on growth as IGFBP-1 is the primary regulator of IGF-I (96).
IGFBP-3 is the predominant and most abundant IGFBP in fetal and postnatal circulation.
It is the main carrier protein of IGF-I and IGF-II, transporting >75% of the IGFs in
circulation (97). The main purpose of IGFBP-3 is to prolong the half-life of IGF-I and
IGF-II (98, 99). IGFBP-3 is able to form a ternary complex with IGF-I or IGF-II and the
85 kDa glycoprotein known as the acid-labile subunit (ALS) (100). Formation of the
ternary complex prolongs the half-life of IGFs and prevents passage through the vascular
endothelium, essentially resulting in an IGF reservoir within the circulation (101).
The predominant IGFBPs which are present in fetal circulation are IGFBP-1, IGFBP-2,
and IGFBP-3 (102) of which only IGFBP-1 is shown to be increased due to fetal hypoxia
(103), further demonstrating the importance of the study of IGFBP-1 for fetal hypoxia.
Like IGFBP-2-3, IGFBP-4-6 do not demonstrate increased protein expression due to
hypoxia (104-106). IGFBP-4 has a role in embryogenesis, where it has been shown to
positively affect IGF-II-mediated actions on embryonic growth (107). Its prenatal role
seems to be limited to enhancing IGF-II actions, which occur primarily at the embryonic
and early fetal stages (2, 58).
IGFBP-5 is structurally similar to IGFBP-3, but unlike IGFBP-3, IGFBP-5 is produced
within various tissues and is not found in fetal circulation (108). The role of IGFBP-5 in
fetal growth is tissue specific, with IGFBP-5 mRNA expressed in muscle, skin, stomach,
and intestinal fetal tissues, suggesting it functions in an autocrine and paracrine manner
where it is able to negatively regulate IGF actions (109, 110).
IGFBP-6 has received less attention than IGFBP-1 to IGFBP-5. IGFBP-6 has been
reported to bind IGF-II with higher affinity than IGF-I. The difference in binding affinity
varies between studies, with 20-fold to 100-fold selective binding preference towards
IGF-II being reported (111, 112). These data suggest that IGFBP-6 is primarily a
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negative regulator of IGF-II action. No role for IGFBP-6 in fetal growth has been
established, however, with IGFBP-6 knockout mice demonstrating no difference in size
and weight compared to control mice (113). Together, these data demonstrate that the
study of hypoxia-induced FGR requires the investigation of IGFBP-1 and its regulation.

1.8 IGFBP-1 and IGF-I in the regulation of fetal growth
My study focuses on IGFBP-1. IGFBP-1 is the major IGFBP responsible for the
regulation of IGF-I-mediated fetal growth (96). During pregnancy, IGFBP-1 functions
primarily as a negative regulator of IGF action and there is an increase in IGFBP-1
present in both the amniotic fluid as well as fetal and maternal circulation (114). It has
been shown that, from as early as sixteen weeks into pregnancy, an inverse correlation
exists between fetal serum IGFBP-1 levels and birth weight (102). This demonstrates the
importance in circulating levels of IGFBP-1 as a regulator and determinant of fetal
growth. Furthermore, fetal IGFBP-1 levels are markedly increased in FGR, particularly in
cases in which uteroplacental blood flow is restricted (102). In the fetus, IGFBP-1 mRNA
is found predominantly in the liver, compared to other IGFBPs which are found in other
specific tissues (106). This promotes the idea of IGFBP-1 functioning as a circulatory
IGFBP in fetal growth, providing regulation of growth to a large number of tissues and
organ systems. IGF-I serum concentrations are thought to be primarily determined by
genetic influences. Conversely, IGFBP-1 concentrations are regulated by both genetic
factors and the fetal environment (106, 115). In this way, IGFBP-1 can act as a growth
regulatory protein which can attenuate growth if the fetal environment is not optimal.
IGFBP-1 serum concentrations can fluctuate to regulate IGF-I bioavailability in both the
short term and long term, responding to potential fetal environment shortcomings such as
reduced nutrient or oxygen availability (115). During pregnancy, the predominant
IGFBPs present in the circulation are IGFBP-1, IGFBP-2, and IGFBP-3, of which
IGFBP-2 functions in a temporal manner to regulate embryonic and early fetal
development (102), and IGFBP-3 binds IGFs in complex with the ALS and maintains a
reservoir of IGFs within circulation (101). Thus, IGFBP-1 is the critical regulator IGFBP
which modulates IGF-mediated fetal growth in mid-to-late gestation. IGFBP-1 does have
roles to play in the regulation throughout life, although its contribution to IGFBP-
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mediated regulation is not predominant like in fetal development. A correlation between
low weight at birth and reduced IGFBP-1 serum levels in girls with precocious pubarche
has been established (116). Low birth weight has also been associated with increased
IGF-I serum levels in prepubertal children, suggesting that catch-up growth occurs postnatally and that these changes are at least in part regulated through the IGFBP-1:IGF-I
axis (117, 118). Interestingly, IGFBP-1 seems to affect homeostatic effects long past
development. In elderly men, high levels of circulating IGFBP-1 have been associated
with the pathogenesis of cardiovascular disease as well as overall mortality (119).
The C terminal domain of IGFBP-1 has been shown to play a role in promoting cell
migration in Chinese hamster ovary and porcine vascular smooth muscle cells (120). It
contains an Arg-Gly-Asp (RGD) domain, known as an integrin recognition sequence
capable of binding the α5β1 integrin, and this interaction is implicated in the mechanism
of induction for cell migration (121). It has further been shown in human trophoblasts
that the IGFBP-1:α5β1 integrin interaction signals downstream to stimulate the MAPK
pathway, and that this mechanism induces human trophoblast migration (122), a
mechanism which may be a critical component of blastocyst implantation into the
endometrial wall in the pre-embryogenesis stage of pregnancy. Whether this mechanism
is cell-type specific remains to be investigated. This demonstrates the ability of IGFBP-1
to perform at least one function independent of IGF-I, although its primary function is to
bind to and sequester IGF-I to reduce IGF-I bioavailability.

1.9 Regulation of IGF-I
phosphorylation

bioavailability

via

IGFBP-1

Like other IGFBPs, IGFBP-1-mediated regulation is more complex than altering IGF-I
bioavailability through IGFBP-1 serum levels. IGFBP-1 is susceptible to post
translational modifications. Phosphorylation of IGFBP-1 is a well established mechanism
by which IGF-I bioavailability is regulated (74, 96). To date, five IGFBP-1
phosphorylation sites have been identified (123-130). Ser95, 98, 101, and 119 are all
phosphoacceptor sites which exist in the linker region of IGFBP-1 – the region of
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IGFBP-1 which also contains sites for proteolysis. Furthermore, Ser169, which exists in
the C terminal domain of IGFBP-1 can be phosphorylated (Figure 1A). We have
previously demonstrated up to a 300-fold increase in binding affinity of IGFBP-1 to IGFI as a result of hypoxia-induced IGFBP-1 phosphorylation at Ser98 and 169 (129).
Conversely, the phosphorylation status of IGFBP-3 and IGFBP-5 (the two other IGFBPs
which have been shown to be phosphorylated) does not alter their binding affinity to IGFI (131). Structural analysis has put forth evidence that the phosphorylation sites of
IGFBP-1 which exist in the linker region and C-terminal domain interact with IGF-I to
enhance its binding (Figure 1B) (124). Interestingly, the phosphorylation state of IGFBP1 may provide inverse effects on the regulation of IGF action. IGFBP-1 samples treated
with alkaline phosphatase, resulting in a dephosphorylated form of IGFBP-1, have been
shown to enhance IGF-I-induced DNA synthesis (132). In vivo, phosphorylated IGFBP-1
is highly predominant in circulation (131), suggesting that this effect may only occur in
localized regions as necessary. This dual effect of either inhibition or enhancement of
IGF-I activity due to the phosphorylation state of IGFBP-1 demonstrates the complexity
and reliance of post-translational modifications on the regulation of IGF-I activity, which
seems to be dependent on upregulation of both kinase and phosphatase activity depending
on the cellular environment. The inhibitory effect of IGFBP-1 on IGF-I actions is a result
of IGFBP-1 binding IGF-I and preventing IGF-I from interacting with its receptor IGF1R (133). However, the mechanism by which dephosphorylated IGFBP-1 enhances IGF-I
activity remains unclear. Although it is understood that hypoxia and nutrient deprivation
induce IGFBP-1 phosphorylation (129), the mechanisms responsible for this induction
are unknown.
Figure 1. IGFBP-1 structure
A. Linear representation of IGFBP-1. Amino acid sequence length of each domain of
IGFBP-1, as well as phosphorylation sites are indicated.
B. Structural model of the IGFBP-1:IGF-I complex, based on the crystal structure of
IGF-I bound to the C-terminal domain of IGFBP-1 and the N-terminal domain of IGFBP4 (199). The N-terminal sequence of IGFBP-1 was inserted into the N-terminus of
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IGFBP-4 coordinates, and the structure was resolved and optimized using the
SwissModel server. Phosphosites Ser98, 101, and 169 are highlighted, demonstrating
their proximity to IGF-I.
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Figure 1. IGFBP-1 structure
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1.10 Regulatory
pathways
involved
in
IGFBP-1
phosphorylation during hypoxia-induced FGR
The molecular mechanisms that regulate fetal growth in FGR caused by hypoxia and
nutrient deprivation need to be understood. Several signaling networks are responsive to
decreased oxygen and nutritional stress, such as the amino acid response (AAR) (134),
the unfolded protein response (UPR) (135), the hypoxia-inducible factor (HIF) (136), and
the mammalian target of rapamycin (mTOR) (137) signaling pathways. We recently
demonstrated a marked inhibition of mTOR signaling linked with IGFBP-1
phosphorylation in baboon fetal liver from maternal nutrient restriction induced FGR
(96). In addition, we reported that inhibition of mTOR in cultured human hepatocellular
carcinoma (HepG2) cells and primary fetal baboon hepatocytes causes increased IGFBP1 phosphorylation (96). Additionally, we previously demonstrated that that hypoxia
induces IGFBP-1 phosphorylation in HepG2 cells (129). Together, these suggest the
involvement of mTOR inhibition in the regulation of IGFBP-1 phosphorylation which
may be occurring in hypoxia.

1.11 The mammalian target of rapamycin (mTOR)
The mammalian target of rapamycin is an evolutionary conserved serine/threonine kinase
which plays multiple roles in the regulation of cell growth and metabolism which are
primarily mediated through modulation of protein translation (138). Figure A1
demonstrates the complexity of the mTOR signaling pathways. Furthermore, mTOR
signaling is highly sensitive to environmental conditions and functions to regulate cell
growth in response to stimuli such as energy levels, stress conditions, and oxygen
availability (137). mTOR exists in two complexes, mTOR Complex 1 (mTORC1) and 2
(mTORC2). Each protein complex contains various proteins associated to mTOR, hence
forming two distinct protein complexes (Figure 2A). mTORC1 is composed of proteins
mTOR, regulatory-associated protein of mTOR (raptor) (139, 140), mammalian lethal
with SEC13 protein 8 (141), PRAS40 (142), TTl1/TEL2 (143), and DEP domaincontaining mTOR interacting protein (DEPTOR) (144). These proteins function in
complex to facilitate and regulate the kinase activity of mTORC1. Similarly, mTORC2 is
composed of proteins mTOR, rapamycin-insensitive companion of mTOR (rictor) (145),
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mammalian stress-activated protein kinase interacting protein 1 (146), Protor½ (147,
148), TTl1/TEL2 (143), and DEPTOR (144). DEPTOR, a shared mTORC1 and
mTORC2 protein, has been shown to play in inhibitory role in the regulation of mTOR
signaling (144). Newly emerging data suggests that DEPTOR functions to basally inhibit
mTOR signaling, as silencing of DEPTOR has been shown to augment the activity of
both mTORC1 and mTORC2 (149, 150).

1.12 mTORC1
mTORC1 has been well established as a regulator of cell growth, with studies showing
that inhibition of mTORC1 results in a decrease in cell size. mTORC1 regulates
numerous processes in the cell including autophagy (151), ribosome biogenesis (152),
mRNA translation (153), and nutrient metabolism (154). Although many processes are
understood to function through mTORC1 signaling, much about the mechanistic
pathways and their components remain unknown. The best example of this is the study of
budding yeast, where numerous mTORC1-mediated processes such as autophagy and
ribosomal protein synthesis are well understood, but much of the molecular pathways
integrated with mTORC1 signaling remain elusive (155).

The study of mTORC1 signaling functionality is a well established practice, where two
proteins directly phosphorylated by mTORC1 have been utilized in determining relative
states of mTORC1 activity. As mTOR is a kinase, the relative phosphorylation levels of
proteins directly phosphorylated by mTORC1 acts as an indicator of mTORC1 activity.
This is useful, for example, in assessing the effectiveness of various mTOR inhibitors on
mTOR activity. The two proteins directly phosphorylated by mTORC1 are S6K (156,
157) and 4E-BP1 (158) (Figure 2A), both of which have important roles in the promotion
of cell growth and protein synthesis. S6K is phosphorylated by mTORC1 at Thr389
(159). Thr389 is part of a hydrophobic motif on S6K (159), and phosphorylation here has
been shown to be required for activation of S6K kinase activity, where mutation of
Thr389 (T389A) abolishes the endogenous kinase activity of S6K (160). Thus,
mTORC1-mediated phosphorylation of S6K is absolutely required for S6K activity. S6K
activation via mTORC1 results in increased mRNA biogenesis as well as cap-dependent
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translation and elongation. Furthermore, S6K activation results in increased protein
translation of various ribosomal proteins (137). Induction of S6K-mediated actions is a
result of S6K directly phosphorylating downstream proteins, as S6K is a kinase itself.
S6K is known so directly phosphorylate S6K1 aly/REF-like target (SKAR), eukaryotic
elongation factor 2 (eEF2K), ribosomal protein S6, programmed cell death 4 (PDCD4),
eIF4B, and CBP80 (157, 159). This is likely an incomplete list, as the complete functions
and actions of S6K are not understood. Furthermore, despite the known list of proteins
targeted and activated by S6K, how these proteins contribute to increased cell size
remains to be determined. 4E-BP1, the other protein well established to be
phosphorylated by mTORC1, functions to promote protein synthesis on a broad scale.
4E-BP1 itself is an inhibitory binding protein, which binds to the eukaryotic translation
initiation factor 4E (eIF4E) and prevents its functions (158). Phosphorylation of 4E-BP1
at Thr70 (159) by mTORC1 prevents 4E-BP1 from binding eIF4E, which in turn is able
to promote cap-dependent translation of numerous proteins (158). In this way, active
mTORC1 signaling is able to promote cell growth through specific pathways via S6K
phosphorylation, as well as broader scale changes to protein synthesis via 4E-BP1
phosphorylation.

1.13 mTORC2
mTORC2 and its functions are less well understood than mTORC1. Like mTORC1,
mTORC2 functions to positively regulate cellular growth processes such as cell
proliferation, survival, and metabolism (161). Interestingly, mTORC2 also seems to
regulate actin cytoskeleton functions within the cell (162), demonstrating the broad
diversity of potential mechanisms regulated by mTORC2 signaling. mTORC2 also
functions as a kinase, but the number of proteins known to be phosphorylated by
mTORC2 is notably lower than mTORC1. mTORC2 is known to directly phosphorylate
protein kinase B (Akt) (163), PKCα (164), and Serum and Glucocorticoid-regulated
Kinase 1 (SGK1) (165) (Figure 2A). Akt activity plays a critical role in the promotion of
cell survival, proliferation, and metabolism in the cell (166). Furthermore, Akt activation
requires phosphorylation at S473 by mTORC2 (167), demonstrating the necessity of
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mTORC2 signaling in the regulation of Akt-mediated growth processes in the cell.
mTORC2 depletion studies have shown that, in the absence of mTORC2 and thus Akt
activity, phosphorylation (and thus activity) of the forkhead box protein O1 (FoxO1) and
FoxO3 transcription factors are markedly reduced (168). These transcription factors
control gene expression of genes involved in metabolism, stress resistance, cell-cycle
arrest, and apoptosis (168). mTORC2-mediated regulation of the actin cytoskeleton has
been investigated, although the mechanisms which regulate mTORC2 actin cytoskeleton
regulation have not been determined (162, 169).

1.14 Rapamycin-mediated mTOR inhibition
Rapamycin is a pharmacological compound which is used as an immunosuppressant,
often for kidney transplants (170). In research, rapamycin is often utilized for mechanistic
studies due to its ability to inhibit mTOR signaling. mTORC2 contains associate protein
rictor, which was named as such due to the traditional belief that mTORC2 is resistant to
rapamycin inhibition. Rapamycin functions by forming a complex with FK506 binding
protein (FKBP12), and this complex is known to inhibit mTOR function by binding to
the FKBP12-rapamycin-binding (FRB) domain of mTOR and mTORC1 which
subsequently prevents the activity of mTORC1. It is speculated that the rapamycinFKBP12 complex inhibits mTORC1 function by disrupting the interaction between
mTOR and raptor (171). mTORC2 does not permit binding of the rapamycin-FKBP12
complex. The reason for this in unknown, although it is speculated that rictor (or an
unidentified component of mTORC2) binding to mTOR occupies the rapamycinFKBP12 binding site or that this binding changes the structure of mTOR such that the
binding site is no longer available for rapamycin-FKBP12 (161). Recently, however, new
data is emerging which shows that prolonged exposure to rapamycin indeed demonstrates
an inhibitory effect on mTORC2, although the mechanism responsible for this inhibition
is not known (96, 163). It is possible that mTORC2 is inhibited by rapamycin due to
uncomplexed mTOR proteins binding to rapamycin and preventing further mTORC2
complex assembly. This would suggest that existing mTORC2 complexes at the time of
rapamycin exposure would be resistant to inhibition, but upon protein turnover complex
formation of mTORC2 is inhibited by mTOR bound to the rapamycin-FKBP12 complex.
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1.15 Hypoxia-mediated mTOR inhibition
It is well established that mTORC1 signaling is inhibited by hypoxia (172, 173). Many
studies have reported this in numerous cell lines including 293 cells (174), MEF cells
(175), and mouse primary hepatocytes (175). mTORC2 activity due to hypoxia is not as
well understood, where studies have reported increases, decreases, and a lack of change
in mTORC2 activity due to hypoxia. It seems that mTORC2 signaling in response to
hypoxia is cell-type specific. For example, mTORC2 activity has been reported to be
increased in PC12 (176), HeLa (176), and HT1080 fibrosarcoma cells (177) due to
hypoxia. No change in mTORC2 activity was reported in PC-3 prostate cancer (178), as
well as COS-7 and 3T3 cells following hypoxic treatment (179). Lastly, mTORC2
inhibition due to hypoxia has been demonstrated in rat myocytes (180), rat
cerebrocortical cells (181), HN13 cells (182), and HepG2 cells (179). The inhibition of
mTORC2 signaling due to hypoxia in HepG2 cells was reported to occur independently
of serum status, with inhibition occurring in both the presence and absence of serum
(179).

1.16 Mechanisms regulating mTOR inhibition in hypoxia
mTORC1 inhibition by hypoxia occurs through the tuberous sclerosis complex 1/2
(TSC1/2) complex signaling pathway (174). Hypoxic stress triggers the activation of the
hypoxia-inducible factor-1α (HIF-1α), a transcription factor which subsequently induces
transcription of response proteins (183). Under normal conditions, HIF-1α is
hydroxylated at conserved proline residues via HIF prolyl-hydroxylases, and this
hydroxylation targets HIF-1α for ubiquitination in the proteasome (184). Hypoxic
conditions result in the inhibition of HIF prolyl-hydroxylases due to the fact that these
proteins use oxygen as a cosubstrate, allowing for cellular accumulation of HIF-1α (185)
(Figure 2B). From here, HIF-1α activity results in the activation of REDD1, which then
induces TSC1/2 activity (186). The high activity state of TSC1/2 alters the ratio of Ras
homologue enriched in the brain (Rheb)GDP to RhebGTP (increasing cellular
RhebGDP), and this change results in the inhibition of mTORC1 signaling (187, 188).
Thus, hypoxia functions on the HIF-1α signaling axis to inhibit mTORC1. The
mechanisms regulating mTORC2 activity in hypoxia are unknown, although it is likely
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that they differ in various cell types due to the variety of responses elicited by hypoxia
which have been reported (176, 178, 189). Whether mTOR inhibition in hypoxia is
responsible for IGFBP-1 phosphorylation remains to be established. Further, the kinase
responsible for directly phosphorylating IGFBP-1 is not known.
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Figure 2. mTOR components and mTORC1 inhibition in response to hypoxia
A. Schematic showing an incomplete list of mTORC1 and mTORC2 associated proteins.
Please see text for a more complete list of mTOR-associated proteins. Also shown are the
most well known downstream substrates directly phosphorylated by mTORC1 and
mTORC2. Use of this schematic is permitted via open access (200).
B. Model of mTORC1 signaling in response to hypoxia. In normoxic conditions (left),
prolyl hydroxylases (PHDs) readily target HIF-1α for degredation, and mTORC1
signaling is not inhibited by the HIF-1α hypoxic response, allowing for mTORC1 activity
to promote cell growth and proliferation through cellular translation. Under hypoxic
conditions (right), PHDs can no longer hydroxylate HIF-1α and thus facilitates the
accumulation of HIF-1α which subsequently functions to inhibit mTORC1 signaling
(201). Please see text for a more detailed description of this mechanism.
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Figure 2.mTOR components and mTORC1 inhibition in response to hypoxia
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1.17 Regulation of IGFBP-1 phosphorylation by mTOR
inhibition via protein kinase CK2
Our recent work with baboon fetal liver from maternal nutrient restriction-induced FGR
demonstrated increased CK2 activity along with mTOR inhibition and increased IGFBP1 phosphorylation in FGR (96). In addition, we reported that IGFBP-1 phosphorylation
via mTOR inhibition was mediated by protein kinase CK2 activity in cultured HepG2
cells and primary fetal baboon hepatocytes (96). CK2 is a conserved serine/threonine
kinase which is regulated by a wide variety of upstream signals (190). It exists as a
tetrameric complex, consisting of α and α’ catalytic subunits as well as two regulatory β
subunits (190). We previously chose to investigate CK2 as a potential kinase for IGFBP1 phosphorylation due to the identification of a consensus sequence within IGFBP-1 for
CK2 interaction (191). Although we have recently established a link between mTOR
inhibition and increased CK2 activity (96), the effect of hypoxia on CK2 activity in
connection with mTOR inhibition and its role in IGFBP-1 phosphorylation during
hypoxia have not been reported.

1.18 Rationale, hypothesis, objectives
Impaired oxygen and nutrient delivery to the fetus are known to result in FGR (24). It is
known that mTORC1 and mTORC2 signaling in HepG2 cells are inhibited by hypoxia
(189), and in the fetal liver of FGR fetuses as we have previously reported (96). IGF-I is
a key regulator of fetal growth and IGF-I bioavailability is determined by IGFBP-1,
which binds IGF-I and inhibits IGF signaling (72). We have previously demonstrated that
hypoxia induces IGFBP-1 phosphorylation which binds IGF-I with markedly higher
affinity (192). We recently also established a link between inhibition of mTOR signaling
and IGFBP-1 hyperphosphorylation (96). Together, these findings provided the basis for
the current mechanistic study in this dissertation and formulation of my hypothesis as
follows.
Hypothesis: Regulation of IGFBP-1 phosphorylation in response to hypoxia occurs via
inhibition of mTOR signaling.
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Objective: The objective of the study was to elucidate the mechanistic role of mTORC1
and/or mTORC2 signaling in regulating IGFBP-1 phosphorylation, and thereby IGF-I
bioavailability, in hypoxia.

The specific aims for this dissertation were as follows:

1.

To investigate the role of mTOR signaling in the induction of IGFBP-1
phosphorylation.

2. A) To investigate the functional role of mTOR signaling in hypoxia-induced
IGFBP-1 phosphorylation.
B) To investigate the involvement of protein kinase CK2 as a kinase for IGFBP-1
phosphorylation induced by rapamycin and/or hypoxia.

3. To demonstrate that regulation of hypoxia-induced IGFBP-1 phosphorylation
requires mTORC1 and/or mTORC2 activity.

Figure 3 illustrates functionally important mTOR-related proteins used in our mechanistic
studies to explore a key link between hypoxia and increased IGFBP-1 secretion and
phosphorylation.
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Figure 3. Functionally important mTOR-related proteins linking mTOR to the
regulation of IGFBP-1
Schematic showing a basic proposed model connecting mTOR signaling to IGFBP-1
secretion and phosphorylation. Key proteins for silencing were raptor and rictor for
mTOR inhibition, and TSC2 and DEPTOR for mTOR activation. Also shown are 4EBP1/S6K and Akt - three proteins directly phosphorylated by mTORC1 and mTORC2,
respectively, which were used as functional readouts for mTORC1 and mTORC2 activity
following treatments. Rapamycin and hypoxia, and their inhibitory effects on mTOR
signaling are also presented.

Figure 3. Functionally important mTOR-related proteins linking mTOR to the
regulation of IGFBP-1
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1.19 Rationale for use of HepG2 cells in this study as a
model for fetal hypoxia
Because the liver is the major source of serum IGFBP-1 in vivo, I used liver-derived
human HepG2 cells to test my hypothesis. HepG2 cells are widely used as a model for
fetal hepatocytes (96, 192-195). They are human liver carcinoma cells which demonstrate
biotransformation characteristics and gene expression patterns similar to primary human
fetal hepatocytes (194, 195). Furthermore, HepG2 cells predominantly express fetal
isoenzymes of both aldolase and pyruvate kinase, and low levels of the cell surface
receptor for asialoglycoproteins – properties which are characteristic of human fetal
hepatocytes (193). We recently validated the use of HepG2 cells for our studies by
demonstrating a high similarity compared to baboon primary fetal hepatocytes in the
response patterns of mTOR inhibition and IGFBP-1 phosphorylation in nutrient-restricted
conditions (96), providing a strong justification for the use of our HepG2 cells as a model
for fetal hepatocytes. Thus, as in our previous reports (96, 129), we used HepG2 cells and
performed mechanistic studies on the role of mTOR in the regulation of hypoxia-induced
IGFBP-1 phosphorylation.
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2.0 Materials and Methods

2

Cell culture

HepG2 cells (ATCC) were cultured in Dulbecco’s Modified Eagle Medium (DMEM)
with nutrient mixture F-12 (DMEM/F-12) supplemented with 10% fetal bovine serum
(FBS) (Invitrogen) at 37°C in atmospheric air (20% O2 with 5% CO2). HepG2 cells were
grown in 10% FBS to 75% confluence in 75cm2 T-75 flasks (BD Biosciences) prior to
plating. Once cells reached 75% confluence, cells were plated via trypsinization (0.5%
trypsin-EDTA, Life Technologies, 1:10 dilution) and re-suspension in 10% FBS.
Following trypsinization but prior to plating, the cell suspension was quantified for cell
count via hemocytometry. 100 µl of cell suspension was combined with 400 µl 0.4%
Trypan Blue (Life Technologies), and of this 20 µl was loaded onto a 0.1 mm depth
Bright-Line hemocytometer (Hausser Scientific) for cell counting. Staining with Trypan
Blue allowed us to perform the Trypan Blue exclusion test of cell viability, in which we
only quantified viable cells. Following hemocytometry, re-suspended cells were plated on
12-well polystyrene culture dishes (BD Biosciences) at a cell density of 1.5x105 viable
cells/well for 24 hours. For treatments, cells were grown to 70% confluency, then media
was changed to 2% FBS overnight or serum free media for 6 hours to allow cell
acclimatization.
P6 cells (mouse embryo fibroblast cells that over-express human IGF-1R) (a gift from Dr.
Renato Baserga, Thomas Jefferson University) were cultured in DMEM with 4.5 g/L Dglucose and 110 mg/L sodium pyruvate using the same cell culture materials, and
treatments were performed in FBS-free conditions.

2.1 Cell media and lysate preparation
Cell culture experiments were concluded with collection of both cell media and cell
lysate. Cell media was collected and immediately stored at -80°C. To collect cell lysate,
plated cells were first rinsed with Dulbecco’s Phosphate Buffered Saline (PBS) (BD
Bioscience) to remove trace amounts of cell media, followed by addition of 175 µl of cell
lysis buffer (Cell Signaling) with Protease Inhibitor Cocktail, Phosphatase Inhibitor
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Cocktail 2, and Phosphatase Inhibitor Cocktail 3 (all from Sigma Aldrich, 1:100
dilution). Collected samples underwent sonification for 15 seconds on ice followed by
13000 RPM centrifugation for 30 minutes at 4°C, after which the supernatant was
collected and the pellet was discarded. Determination of total protein in the cell lysate
occurred via Bradford protein assay, followed by storage at -80°C.

2.2 Bradford protein assay
5 µl aliquots of cell lysis buffer were diluted with Milli-Q water (1:10 dilution) and
plated in triplicate 10 µl aliquots on a Linbro® 96-well Microplate (MP Biomedicals)
along with duplicate 10 µl aliquots of protein standards at concentrations of 0, 25, 125,
250, and 500 µg/ml (Thermo Scientific). 200 µl of Bradford reagent (Bio-Rad
Laboratories Inc.) were added to each well followed by sealing of the wells with an
adhesive cover, and the mixtures were allowed to incubate at room temperature for 5
minutes. The plate was then loaded onto a Thermo Labsystems Multiskan Ascent
photometer (Thermo Scientific), and relative absorbance (representing protein
concentration) was determined using light at 595 nm generating protein concentrations
with units of mg/ml.

2.3 Rapamycin treatment
Plated HepG2 cells in culture had their media changed to 2% FBS overnight prior to
rapamycin treatment. Rapamycin was diluted to 100 nM in DMEM/F-12 cell media
supplemented with 2% FBS, followed by syringe-based (BD Biosciences) filtration
(Puradisc 0.2 µm, Whatman GE Healthcare) to ensure sterilization. HepG2 cells were
treated with 100 nM rapamycin for 24 hours. Control media contained 2% FBS only.
Following treatments, the cell media and cell lysate were prepared and stored at -80°C.

2.4 Hypoxic treatment
HepG2 cells were incubated for overnight in 2% FBS media overnight or 6 hrs in FBSfree DMEM/F-12. Subsequently, the media was replaced with new 2% FBS or FBS-free
DMEM/F-12 and cell cultures were then placed in either in an incubator with
atmospheric air and 5% CO2 (normoxia) or a hypoxia chamber (Billups–Rothenburg),

28

which was flushed with a 1%O2, 5%CO2, balanced N2 gas mixture (BOC Canada Ltd) for
5 minutes to ensure saturation. The cells in the sealed chamber were placed in a tissueculture incubator at 37°C on an orbital shaker at low speed to facilitate continued gas
exchange between the cell environment and the surrounding air. Cells were cultured in
normoxia or hypoxia for 24 hours during rapamycin and siRNA treatments. Cell media
and cell lysate were collected following 24 hour exposure.

2.5 Cell viability assay
We tested the effect of our rapamycin and hypoxia treatments on cell viability via the
trypan blue exclusion assay. Following rapamycin and hypoxia treatments, cells were
trypsinized and resuspended in 10% FBS. Cell suspensions were diluted 1:1 with 0.4%
trypan blue and counted using the Countess Automated Cell Counter (Life Technologies,
Carlsbad, CA). Cell viability was determined as a measure of live/total cells.

2.6 IGF-I receptor assay
P6 cells (a BALB/c3T3 cells derivative), which are mouse fibroblast cells that overexpress human IGF-1R, were plated at ~1.5×106 cells per well and grown to 50%
confluence in 12-well plates in DMEM with D-Glucose and sodium pyruvate
supplemented with 10% FBS. P6 cells were exposed to serum free media for 6 hours
prior to treatment. As a positive control, human recombinant IGF-I (Tercica Inc.) was
diluted in 1 ml of P6 cell media at a concentration of 100 ng/ml in the absence of IGFBP1. Prior to exposure on P6 cells, equal total IGFBP-1 from conditioned HepG2 cell media
(approximately 1000 ng/ml) from rapamycin, hypoxia, and rapamycin+hypoxia treated
HepG2 cells (as well as media from untreated HepG2 cells) was combined with P6 cell
media to total 1 ml with a 100 ng/ml dilution of IGF-I, and allowed to incubate at room
temperature for 2 hours. This allowed for variance in degree of IGFBP-1 phosphorylation
between samples, but not variance in levels of total IGFBP-1. P6 cells were then rinsed
with PBS, and then exposed to the cell media mixtures for 10 minutes. The cell media
mixtures were then aspirated, and 175 ml of cell lysis buffer was added to the wells. The
cell lysates were analyzed via western blotting to assess relative levels of IGF-1R
phosphorylation as a result of IGF-I stimulation.
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2.7 Protein kinase CK2 activity assay
CK2 activity was measured in HepG2 whole-cell lysates using the synthetic peptide
substrate RRRDDDSDDD. Assays were performed for 5 min at 30 °C in a final reaction
volume of 30 μl containing 50 mM Tris-Cl (pH 7.5), 150 mM NaCl, 10 mM MgCl2, 1
mM dithiothreitol, and 0.1 mM ATP (specific activity 500–700 cpm/pmol) (PerkinElmer)
and RRRDDDSDDD (0.1 mM). Reactions were initiated by addition of 9 μl of cell
extract or immunocomplex and were terminated by spotting 10 μl on P81
phosphocellulose paper as described previously (96). The papers were washed four times
in 1% phosphoric acid and once in 95% ethanol. Once dry, papers were immersed in
scintillant and counted in a Beckman LS 5801 scintillation counter.

2.8 RNA interference-mediated silencing
Silencing raptor and/or rictor individually or combined, DEPTOR, and TSC2 in HepG2
cells (~1.5×106 cells per well grown to 70% confluence in 12-well plate) was achieved
using transfection with 100 nM siRNA (Sigma-Aldrich) and Dharmafect transfection
reagent 4 (Thermo Scientific). HepG2 cells were switched to serum free DMEM/F-12
cell media for 6 hours prior to transfection to allow for cell acclimatization. During
acclimatization, siRNA cell media was prepared. siRNAs were incubated in 100 µl/well
serum free media for 5 minutes. Separately, 5 µl/well Dharmafect transfection reagent 2
was incubated in 100 µl/well serum free media for 5 minutes to allow for emulsification.
Following 5 minute incubations, siRNAs and transfection reagent were combined (total
200 µl/well) and allowed to incubate for 20 minutes for further emulsification. All
incubations were performed at room temperature. Following serum free cell
acclimatization and siRNA:transfection reagent emulsification, HepG2 cells were rinsed
with PBS and exposed to the siRNA:transfection reagent mixture (200 µl/well) for 2.5
hours. 800 µl serum free cell media was added after 2.5 hours to yield a total of 1 ml cell
media/well. siRNA treatment occurred for 72 hours. Immediately following transfection,
cells were cultured for 48 hours in normoxia (20% O2), followed by an additional 24
hours either in normoxia or in hypoxia (1% O2). The efficiency of target silencing was
determined at the protein and functional levels using western blot analysis.
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2.9 SDS-PAGE and western blots
Equal amounts of cell lysate protein (20-50 µg) were used to determine phosphorylation
and total expression of p70S6K at Thr389, 4E-BP1 at Thr70, Akt at Ser473, IGF-1R at
Tyr1135, as well as total expression levels of CK2 (α, α’, and β), albumin, and siRNA
target proteins. IGFBP-1 secretion (8 µl) and phosphorylation (40 µl) at Ser101, 119 and
169 by HepG2 cells were determined using equal volume of cell media. As in our
previous study, IGFBP-1 secretion and phosphorylation in cell media samples were
normalized via equal loading of sample, as there are no valid loading controls available
for secreted proteins. For immunoblot analysis, either 5% skim milk or 5% BSA in Trisbuffered saline (TBS) plus 0.1 % Tween-20 or 0.5% gelatin in PBS (albumin blotting)
were used for blocking. All primary antibodies were obtained from Cell Signaling
Technologies (Beverly, MA) with the exception of the monoclonal antihuman IGFBP-1
(mAb 6303) (Medix Biochemica) and a IGFBP-1 polyclonal antibody (a gift from Dr. R.
Baxter, Kolling Institute of Medical Research), and polyclonal albumin antibody (Bethyl
Laboratories). Custom IGFBP-1 polyclonal antibodies targeting Ser101, Ser119, and
Ser169 were generated at YenZyme Antibodies LLC and were used for detection of
phosphorylation at the three respective sites. Primary antibodies were used at a dilution of
1:1000 except for total IGFBP-1 antibody that was 1:10000 and β-actin 1:5000.
Peroxidase-labeled goat-anti mouse or goat-anti rabbit antibodies (1:10000, Bio-Rad)
were used as secondary antibodies.
To monitor the progress of electrophoresis and electrophoretic transfer, and to visualize
protein marker bands directly on our western blots, 8 µl of BenchMark™ Pre-Stained
Protein Ladder and 2 µl of MagicMark™ XP Western Protein Standard (both from Life
Technologies), respectively, were loaded into one of the lanes of the gel. Protein
separations were conducted on 1.5 mm SDS polyacrylamide gels at concentrations of 8%,
10%, 12%, and 15% (Bio Rad). Gels were run for 30 minutes at 80 V, followed by
approximately 1.5 hours at 120 V. Electrophoretic transfer was performed at 0.8 A for 1
hour in a Bio-Rad Trans-Blot® Cell apparatus onto nitrocellulose membranes (Pall Life
Sciences), followed by blocking for 1 hour at room temperature on a shaker with
previously mentioned solutions. Incubation in primary antibodies occurred overnight at
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4°C on a shaker to ensure complete membrane antibody exposure. The membranes were
then washed with TBS + 0.1% Tween (BioShop) 3 times for 10 minutes each on a shaker
at room temperature, followed by a 1 hour incubation in secondary antibody on a shaker
at room temperature. In order to wash away excess antibody, the membranes were
washed 3 more times for 10 minutes each on a shaker at room temperature. The
membranes were then exposed to 4 ml of enhanced chemiluminescence (ECL) reagents
and imaged on a VersaDoc Imager (Bio-Rad). Band intensities were determined using
densitometry and Image Lab (Beta 3) software (Bio-Rad).

2.10 Two-dimensional immunoblot of IGFBP-1
Two-D immunoblot analysis with HepG2 cell media (~150 μl) using polyclonal IGFBP-1
antibody was performed as previously described (96, 130, 192, 196, 197). Breifly, Equal
volumes (100 μl) of cell media were desalted and concentrated 10-fold using 10-kDa
Mr cutoff (MWCO) Centricon tubes (Pall Life Sciences). Desalted samples were
reconstituted

with

rehydration

buffer

{8 M urea,

2%

(3-[(3-cholamidopropyl)

dimethylammonio]- 1-propanesulfonate (CHAPS) (Bio-Rad), 50 mM dithiothreitol, 0.2%
Biolyte (Bio-Rad), (pH 3–10 ampholyte), and 0.001% bromophenol blue} and transferred
onto a polyvinylidene fluoride membrane by wet transfer (31). Membranes were blocked
in 4% nonfat dry milk and then incubated overnight with IGFBP-1 polyclonal antibody
(1:10,000 dilution). The goat anti-rabbit HRP-conjugated antibody (1:8000 dilution) was
used as a secondary antibody, and proteins were visualized using the ECL Plus system.

2.11 Data presentation and statistics
Statistics were performed using GraphPad Prism 5 (Graph Pad Software Inc.). For each
protein quantified, the mean density of the control sample bands was assigned an
arbitrary value of 100. All individual densitometry values were expressed relative to this
mean. To compare means, Student t-test and ANOVA were used and the results were
expressed as Mean ± SEM. Significance was accepted at P <0.05.
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3.0 Results

3

Results divided into three aims
Aim 1: To investigate the role of mTOR signaling in the
induction of IGFBP-1 phosphorylation

3.1 Rapamycin induces IGFBP-1 secretion and
phosphorylation in a dose dependent manner
We first determined the effect of rapamycin on IGFBP-1 secretion and phosphorylation
in a dose dependent manner. We tested the effects of 3 concentrations of 24 hour
rapamycin treatment on HepG2 cells – 50, 75, and 100 nM. IGFBP-1 secretion was
significantly increased by both 75 and 100 nM of rapamycin (Figure 4A). We next
assessed IGFBP-1 phosphorylation, and again found that a significant increase in IGFBP1 phosphorylation was detected at both 75 and 100 nM. Phospho-sites Ser101 (Figure
4B) and Ser169 (Figure 4D) had high levels of induced phosphorylation due to 75 and
100 nM treatment, demonstrating a plateau effect in the degree of phosphorylation seen.
Interestingly, phosphorylation at Ser119 (Figure 4C) was notably higher at 100 nM than
at 75 nM rapamycin treatment. Due to the highest induction in Ser119 phosphorylation
seen at 100 nM and the plateau effect seen by phosphorylation at Ser101 and Ser169, as
well as total secreted IGFBP-1, we performed subsequent rapamycin treatments at 100
nM as in the literature (163, 169, 198) and our previous study (96).
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Figure 4. The effect of dose dependent rapamycin treatment on IGFBP-1 secretion
and phosphorylation in HepG2 cells
HepG2 cells were cultured for 24 hours with 0, 50, 75, and 100 nM rapamycin (n=3
each).
A. A representative western blot of IGFBP-1 conditioned media of control and rapamycin
treated HepG2 cells (n=3 each) using equal aliquots of conditioned media. Rapamycin
treatment of HepG2 cells significantly increased IGFBP-1 secretion. A strong induction
of IGFBP-1 secretion was seen at 75 and 100 nM rapamycin treatment. Values are
displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.0001 versus control;
One-way analysis of variance; Dunnet’s Multiple Comparison Test; n=3.
B-D. Representative western blots of phosphorylated IGFBP-1 at Ser101, 119 and 169 in
conditioned media of control and rapamycin treated HepG2 cells (n=3 each) using equal
aliquots of conditioned media. Rapamycin treatment of HepG2 cells significantly
increased IGFBP-1 phosphorylation at all three serine sites. A strong induction of
IGFBP-1 phosphorylation was seen at all three sites with 100 nM rapamycin treatment.
Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.0001 versus
control; One-way analysis of variance; Dunnet’s Multiple Comparison Test; n=3.
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Figure 4. The effect of dose dependent rapamycin treatment on
IGFBP-1 secretion and phosphorylation in HepG2 cells
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3.2 Rapamycin inhibits mTORC1 and mTORC2 signaling in
a time dependent manner
In order to assess the effects of rapamycin on mTORC1 and mTORC2 signaling in
HepG2 cells, we treated HepG2 cells with 100 nM rapamycin for 0, 1, 2, 3, 6, and 12
hours. mTORC1 signaling, as assessed by S6K phosphorylation (Thr389), was
significantly inhibited by rapamycin within the first hour of treatment (Figure 5A).
mTORC2 signaling, as assessed by Akt phosphorylation (Ser473), was significantly
inhibited by rapamycin between 3 and 6 hours into the treatment (Figure 5B). This
demonstrated that a prolonged exposure to 100 nM rapamycin was sufficient to inhibit
both mTORC1 and mTORC2 signaling in HepG2 cells.
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Figure 5. The effect of time dependent rapamycin treatment on mTORC1 and
mTORC2 signaling in HepG2 cells.
HepG2 cells were cultured with and without rapamycin (100 nM) (n=3 each) for 0, 1, 2,
3, 6, or 12 hours.
A. A representative western blot of S6K (Thr389) phosphorylation in HepG2 cell lysate
following time dependent rapamycin treatment (n=3). Equal loading (35 µg) was
performed. Rapamycin inhibited mTORC1 signaling after 1 hour of rapamycin treatment.
B. A representative western blot of Akt (Ser473) phosphorylation in HepG2 cell lysate
following time dependent rapamycin treatment (n=3). Equal loading (30 µg) was
performed. Rapamycin inhibited mTORC2 signaling after 6 hours of rapamycin
treatment. Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p <
0.0001

versus

control;

One-way

Dunnet’s Multiple Comparison Test; n=3.

analysis

of

variance;
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Figure 5. The effect of time dependent rapamycin treatment on mTORC1
and mTORC2 signaling in HepG2 cells.
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3.3 Rapamycin inhibits mTOR signaling and induces
IGFBP-1 secretion and phosphorylation
Based on the effectiveness of rapamycin at inhibiting both mTORC1 and mTORC2
signaling within 12 hours, and the induction of IGFBP-1 seen by 100 nM of rapamycin at
24 hours, we validated our findings by treating HepG2 cells with 100 nM of rapamycin
for 24 hours and determined the effects of this treatment on mTORC1 and C2 signaling,
as well as IGFBP-1 secretion and phosphorylation. Indeed, our 24 hour treatment
significantly inhibited mTORC1 and mTORC2 signaling (Figure 6A-B). The treatment
also significantly increased IGFBP-1 secretion (Figure 6C) and phosphorylation at
Ser101, 119, and 169 (Figure 6D-F), validating our subsequent use of 100 nM rapamycin
treatment for 24 hours.

39

Figure 6. The effect of rapamycin treatment on mTORC1 and mTORC2 signaling
and IGFBP-1 secretion and phosphorylation in HepG2 cells.
HepG2 cells were cultured for 24 with and without rapamycin (100 nM) (n=3 each).
A. A representative western blot of S6K (Thr389) phosphorylation in HepG2 cell lysate.
Equal loading (35µg) was performed. Rapamycin treatment inhibited mTORC1
signaling. B. A representative western blot of Akt (Ser473) phosphorylation in HepG2
cell lysate. Equal loading (20µg) was performed. Rapamycin treatment inhibited
mTORC2 signaling. C. A representative western blot of IGFBP-1 in conditioned media
of HepG2 cells using equal aliquots of conditioned media. Rapamycin treatment
increased IGFBP-1 secretion. D-F. Representative western blots of phosphorylated
IGFBP-1 at Ser101, 119, and 169 in conditioned media of HepG2 cells using equal
aliquots of conditioned media. Rapamycin treatment increased IGFBP-1 phosphorylation
at all three sites. Values are given as means + SEM. P < 0.05 versus control; unpaired
Student’s t test.
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Figure 6. The effect of rapamycin treatment on mTORC1 and mTORC2 signaling
and IGFBP-1 secretion and phosphorylation in HepG2 cells.
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Aim 2A: To investigate the functional role of mTOR signaling
in the hypoxia-induced IGFBP-1 phosphorylation
3.4 Rapamycin and/or hypoxia inhibit mTOR signaling
We determined the phosphorylation of mTORC1 and C2 downstream targets as
functional readouts in response to rapamycin and/or hypoxia. As shown in Figure 7A-B,
rapamycin caused a profound decrease in the phosphorylation of 4E-BP1 at Thr70 (-44%)
and Akt at Ser473 (-74%) demonstrating that 100 nM rapamycin significantly inhibits
both mTORC1 and C2 signaling in HepG2 cells, in agreement with our recent report
(96). Further, data in Figure 7A shows that phosphorylation of 4E-BP1 (Thr70) was
significantly reduced in response to hypoxia, or in hypoxia combined with rapamycin.
The degrees to which mTORC1 activity were inhibited in response to rapamycin,
hypoxia or rapamycin combined with hypoxia were not significantly different from each
other. Similarly, phosphorylation of Akt at Ser473 (mTORC2 functional readout) was
markedly inhibited by rapamycin, hypoxia, and rapamycin combined with hypoxia
(Figure 7B). These data demonstrate that both mTORC1 and C2 signaling are inhibited to
similar degrees in response to rapamycin and/or hypoxia (Figure 7A-B).

3.5 mTOR inhibition by rapamycin and/or hypoxia increase
IGFBP-1 phosphorylation
To establish that mTOR signaling constitutes a key molecular link between altered
oxygen levels and changes in IGFBP-1 secretion and phosphorylation, we examined the
effects of rapamycin and hypoxia on IGFBP-1 secretion and phosphorylation in HepG2
cells. Using equal volumes of HepG2 cell media, we demonstrated that IGFBP-1
secretion was significantly increased by both rapamycin (+167%), or hypoxia (+162%),
however these effects were not additive when rapamycin and hypoxia were combined
(Figure 7C). To assess IGFBP-1 phosphorylation qualitatively, we resolved IGFBP-1
phosphoisoforms in cell media by 2-D immunoblotting (Figure 7D, top left panel), where
an increased number of spots shifting to the left (positive) represented increased
phosphorylation.

mTOR

inhibition

using

rapamycin

caused

a

pronounced
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hyperphosphorylation of IGFBP-1 (Figure 7D, top right panel) and hypoxia had a similar
effects (Figure 7D, bottom left panel). Interestingly, in the presence of rapamycin,
hypoxia did not cause any additional phosphorylation of IGFBP-1 (Figure 7D, bottom
right panel). These results support the hypothesis that hypoxia induces IGFBP-1
hyperphosphorylation mediated by mTOR inhibition. Using phosphosite specific
antibodies, we further demonstrated a pronounced increase in phosphorylation at the
three specific serine sites Ser101, 119 and 169 (Figure 7E-G) in response to rapamycin,
hypoxia or combined rapamycin+hypoxia, with no significant differences between these
treatments (Figure 7E-G). These findings suggest that induction of IGFBP-1 secretion
and phosphorylation due to hypoxia is mediated via inhibition of mTOR signaling. We
also validated the use of equal loading for cell media in our western blots by assessing
albumin secretion. Rapamycin, hypoxia, as well as combined rapamycin+hypoxia all
moderately yet significantly reduced albumin secretion (Figure A2). As phospho-IGFBP1 levels were increased in conditions where we were also able to demonstrate a reduction
in albumin secretion, we concluded that equal loading of cell media for western blotting
is a suitable loading control.
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Figure 7. The effect of rapamycin and/or hypoxia treatment on IGFBP-1 secretion
and phosphorylation
HepG2 cells were cultured for 24 hours in normoxia (20% pO2) or in low oxygen (1%
pO2, hypoxia) with and without rapamycin (100 nM) (n=3 each).
A. A representative western blot of 4E-BP1 (Thr70) phosphorylation in HepG2 cell
lysate. Equal loading (20µg) was performed. Both rapamycin and hypoxia treatments
separately inhibited mTORC1 signaling. Rapamycin+hypoxia treatment combined
inhibited 4E-BP1 (Thr70) phosphorylation, but not to a further degree than either
treatment alone. B. A representative western blot of Akt (Ser473) phosphorylation in
HepG2 cell lysate. Equal loading (30µg) was performed. Both rapamycin and hypoxia
treatments separately inhibited mTORC2 signaling. Rapamycin+hypoxia treatment
combined inhibited Akt (Ser473) phosphorylation, to a similar degree as either treatment
alone. C. A representative western blot of total IGFBP-1 in cell media of control,
rapamycin, hypoxia and rapamycin+hypoxia treated HepG2 cells (n=3 each) using equal
aliquots of cell media. Separate rapamycin and hypoxia treatment of HepG2 cells for 24
hrs significantly increased IGFBP-1 secretion. A combined treatment of rapamycin and
hypoxia also induced IGFBP-1 secretion, but with no additional increase than either
treatment alone, suggesting that induction of IGFBP-1 secretion in hypoxia is mediated
by mTOR inhibition. D. A representative western blot of IGFBP-1 phosphoisoforms in
cell media resolved by 2-D immunoblotting (top left panel), where an increased number
of spots shifting to the left (positive) represent increased phosphorylation. Equal loading
(volume) was performed. Both rapamycin (top right panel) and hypoxia (bottom left
panel) treatments separately induced IGFBP-1 phosphorylation. In the presence of
rapamycin, hypoxia did not cause any additional changes in phosphorylation of IGFBP-1
(bottom right panel) compared to either treatment alone. E-G. Representative western
blots of phosphorylated IGFBP-1 at Ser101, 119 and 169 in cell media of control,
rapamycin, hypoxia and rapamycin+hypoxia treated HepG2 cells (n=3 each) using equal
aliquots of cell media. Rapamycin and hypoxia treatment of HepG2 cells individually
increased IGFBP-1 phosphorylation significantly at all three serine sites. Combinatorial
treatment (rapamycin +hypoxia) did not increase IGFBP-1 phosphorylation more than
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either treatment alone, suggesting that hypoxic effects on IGFBP-1 phosphorylation
(Ser101, 119, and 169) are mediated through mTOR inhibition. Values are displayed as
mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.0001 versus control; One-way
analysis of variance; Dunnet’s Multiple Comparison Test; n=3.
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Figure 7. The effect of rapamycin and/or hypoxia treatment on
IGFBP-1 secretion and phosphorylation
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3.6 Rapamycin and/or hypoxia treatments do not alter cell
viability
We tested cell viability as a result of our rapamycin, hypoxia, and combined
rapamycin+hypoxia treatments using the Trypan Blue exclusion assay using the Countess
Automated Cell Counter. This was done to ensure that relative fold inductions of IGFBP1 observed were reflective of the treatments and not altered due to cell death. Cell
viability between treatments was remarkably similar (thus no detectable error bars),
demonstrating that our treatments were not causing cell death and that the inductions of
IGFBP-1 observed were accurate (Figure A3).

3.7 IGFBP-1 phosphorylation in response to rapamycin
and/or hypoxia inhibit IGF-I function
We utilized our IGF-I receptor β (IGF-1Rβ) autophosphorylation assay in P6 cells (96,
197) to assess the functional effects of IGFBP-1 phosphorylation. P6 cells incubated with
IGF-I but without HepG2 cell media and thus no IGFBP-1 (positive control)
demonstrated a marked increase in IGF-1R phosphorylation (+2495%) compared to P6
cells without IGF-I or HepG2 cell media (negative control) (Figure 8). This demonstrated
the ability of IGF-I to stimulate IGF-1R autophosphorylation in P6 cells. When P6 cells
were incubated with IGFBP-1 in untreated (basal) HepG2 cell media+IGF-I (control), a
significant reduction in IGF-1R autophosphorylation was observed (-72%) compared to
P6 cells incubated with IGF-I only. This suggested that basal levels of IGFBP-1 secreted
by HepG2 cells (control) were able to sequester bioavailable IGF-I and subsequently
reduce IGF-1R signaling. A further reduction (-58% to -64%) in IGF-1R
autophosphorylation was observed when P6 cells were incubated with HepG2 cell media
from either rapamycin, hypoxia, or rapamycin+hypoxia combined + IGF-I, compared to
untreated (basal) HepG2 cell media (Figure 8). As equal concentration of total IGFBP-1
from HepG2 cell media was used to activate IGF-1R in P6 cells, this data suggest that
inhibition

in

IGF-1R

autophosphorylation

was

caused

mainly

by increased

phosphorylation of IGFBP-1. Collectively, these data provide evidence for a key role of
mTOR inhibition in linking hypoxia to increased IGFBP-1 phosphorylation and reduced
IGF-I bioavailability in cells.
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Figure 8. The effect of IGFBP-1 phosphorylation due to rapamycin, hypoxia, and
combined rapamycin+hypoxia in HepG2 cell media on IGF-1R autophosphorylation
in P6 cells
A representative western blot of P6 cell IGF-1R phosphorylation. HepG2 cells were
treated with or without rapamycin (Rapa) for 24 hours in normoxia (20% pO2) or in low
oxygen (1% pO2, hypoxia) (n=3 each), followed by HepG2 cell media collection. Equal
concentrations of IGFBP-1 were mixed in P6 serum free cell media with human
recombinant IGF-I (100 ng/ml) for 2 hours to allow IGFBP-1-mediated IGF-I
sequestration, followed by 10 minute exposure to P6 cells to induce P6 cell IGF-Imediated IGF-1R autophosphorylation. Equal loading of P6 cell lysate (30μg) was
performed. Increased IGFBP-1 phosphorylation due to rapamycin, hypoxia, or combined
rapamycin+hypoxia (R+H) resulted in significantly decreased IGF-1R activation. Values
are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.0001 versus control;
One-way analysis of variance; Dunnet’s Multiple Comparison Test; n=3.
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Figure 8. The effect of IGFBP-1 phosphorylation due to rapamycin, hypoxia, and
combined rapamycin+hypoxia in HepG2 cell media on IGF-1R autophosphorylation
in P6 cells
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Aim 2B: To investigate the functional role of mTOR signaling
in the hypoxia-induced IGFBP-1 phosphorylation
3.8 mTOR inhibition and hypoxia increase CK2 activity but
not expression
As we previously demonstrated a link between increased CK2 expression and activity
and FGR in baboon fetal liver as well as a mechanistic link between mTOR inhibition
and increased CK2 activity in HepG2 cells, we investigated the effects of rapamycin and
hypoxia on CK2 expression and activity. In agreement with our previous findings (96),
rapamycin did not alter the expression levels of all three CK2 subunits (α, α’, and β).
Furthermore, hypoxia did not significantly alter the expression levels of all three
subunits. CK2α and CK2β levels were slightly decreased by hypoxia and
rapamycin+hypoxia, but not to a significant degree (Figure 9A-C). The lack of increase
in CK2 subunit expression during rapamycin and hypoxia was consistent when
rapamycin and hypoxia treatments were combined. This suggests that both mTOR
inhibition and hypoxia do not regulate CK2 at the transcriptional or translational levels in
HepG2 cells, which is in agreement with our HepG2 cell rapamycin treatment study (96).
We measured CK2 activity using our previously established CK2
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P phosphorylation

assay (96, 126) to investigate the effect of mTOR inhibition and hypoxia on CK2 activity
in HepG2 cells. CK2 activity was significantly increased (+145%) to similar levels in
rapamycin, hypoxia, and combined rapamycin+hypoxia treatments, with no additive
effect seen when treatments were combined (Figure 9D). This data suggests that HepG2
cell CK2 activity in hypoxia is regulated through mTOR inhibition, which is in alignment
with our data on hypoxia-induced IGFBP-1 in HepG2 cells.
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Figure 9. The effect of rapamycin and hypoxia on CK2 protein expression and
activity in HepG2 cells.
A-C. Representative blots of CK2α, CK2α’, and CK2β expression in lysates of HepG2
cells after 24 hours of rapamycin, hypoxia, or rapamycin+hypoxia treatments. Equal
protein loading (30 µg) was performed. Rapamycin, hypoxia, and combined
rapamycin+hypoxia did not significantly alter the expression of the three CK2 subunit
proteins. D. Summary of CK2 activity in HepG2 cell lysate after 24 hours of rapamycin,
hypoxia, or rapamycin+hypoxia treatments. The kinase activity assays were performed
using equal amounts of protein from whole-cell lysates. Rapamycin, hypoxia, and
rapamycin+hypoxia treatments significantly increased CK2 activity to similar levels.
Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.0001 versus
control; One-way analysis of variance; Dunnet’s Multiple Comparison Test; n=3.
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Figure 9. The effect of rapamycin and hypoxia on CK2 protein expression and
activity in HepG2 cells.
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Aim 3: To demonstrate that regulation of hypoxia-induced
IGFBP-1 phosphorylation requires mTORC1 and/or
mTORC2 activity
3.9 mTOR inhibition by raptor and rictor silencing induces
IGFBP-1 secretion and phosphorylation
We tested the hypothesis that mTOR inhibition mechanistically links hypoxia to IGFBP1 hyperphosphorylation using an RNA interference strategy to silence raptor or rictor
individually in presence and absence of hypoxia. We first confirmed that our RNA
interference approach efficiently silenced the mTORC1 and mTORC2 signalling
pathways individually or in combination with a significant reduction in raptor and rictor
protein expression (Figure 10A-B).

Moreover, as shown in Figure 10C, mTORC1 activity was reduced both due to raptor
silencing (-40%) as well as combined raptor+rictor silencing (-48%), as assessed by a
reduced phosphorylation of 4E-BP1 (Thr70). Similarly, mTORC2 activity was reduced
by rictor (-52%) and combined raptor+rictor silencing (-60%) as indicated by a reduction
in phosphorylation of Akt (Ser473) (Figure 10D). Thus we demonstrated the ability of
raptor and rictor silencing to functionally inhibit mTORC1 and mTORC2 signaling,
respectively.

Next, we assessed the effects of raptor and/or rictor silencing on IGFBP-1 secretion and
phosphorylation. IGFBP-1 secretion increased following siRNA targeting raptor, rictor
and combined raptor+rictor silencing (Fig 10E). In addition, we demonstrated that
IGFBP-1 phosphorylation was increased by selective mTORC1 or mTORC2 inhibition,
as well as combined mTORC1+mTORC2 inhibition (Figure 10F-H). Although
significant increases in phosphorylation occurred at all three specific sites (Ser101
+181%, 119 +198%, and 169 +245%), phosphorylation at Ser169 was most prominently
effected. Inhibition of mTORC1, mTORC2, or combined mTORC1+mTORC2 all
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increased phosphorylation to similar levels (Figure 10F-H). These data indicate that both
mTORC1 and mTORC2 regulate IGFBP-1 secretion and phosphorylation.
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Figure 10. The effect of raptor and rictor silencing on IGFBP-1 secretion and
phosphorylation
HepG2 cells were cultured for 72 hours with scrambled, raptor, rictor, or combined
raptor+rictor siRNA (100 nM) (n=3 each).
A. A representative western blot raptor in HepG2 cell lysate. Equal loading (50µg) was
performed. Raptor and combined raptor+rictor siRNA reduced total raptor protein
expression to similar levels. B. A representative western blot rictor in HepG2 cell lysate.
Equal loading (50µg) was performed. Rictor and combined raptor+rictor siRNA reduced
total rictor protein expression to similar levels. C. A representative western blot of 4EBP1 (Thr70) phosphorylation in HepG2 cell lysate. Equal loading (20µg) was performed.
Raptor and combined raptor+rictor silencing inhibited 4E-BP phosphorylation. D. A
representative western blot of Akt (Ser473) phosphorylation in HepG2 cell lysate. Equal
loading (30µg) was performed. Rictor as well as combined raptor+rictor silencing both
inhibited Akt phosphorylation to similar degrees. E. A representative western blot of
IGFBP-1 in cell media of scrambled, raptor, rictor, and combined raptor+rictor siRNA
treated HepG2 cells (n=3) using equal aliquots of cell media. Raptor, rictor, and
combined raptor+rictor siRNA all significantly increased IGFBP-1 secretion, with the
greatest

induction

occurring

due

to

combined

raptor+rictor

silencing.

F-H.

Representative western blots of phosphorylated IGFBP-1 at Ser101, 119 and 169 in cell
media of scrambled, raptor, rictor, and combined raptor+rictor siRNA treated HepG2
cells (n=3 each) using equal aliquots of cell media. Raptor, rictor, and combined
raptor+rictor siRNA all significantly increased IGFBP-1 phosphorylation at all three
sites, suggesting inhibition of either complex is sufficient to induce IGFBP-1
phosphorylation. Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05,
***p <

0.0001

versus

control;

Dunnet’s Multiple Comparison Test; n=3.

One-way

analysis

of

variance;
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Figure 10. The effect of raptor and rictor silencing on IGFBP-1 secretion and
phosphorylation
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3.10 Activation of mTORC1 and mTORC2 by DEPTOR
silencing prevents hypoxia-induced IGFBP-1 secretion
and phosphorylation
To confirm that mTORC1 and/or mTORC2 mediate the increase in IGFBP-1 secretion
and phosphorylation in response to hypoxia, we determined the effect of hypoxia on
IGFBP-1 secretion and phosphorylation in cells in which mTORC1 and C2 were
activated. To activate mTOR we silenced DEPTOR, an endogenous mTORC1 and
mTORC2 inhibitor.
We first validated that DEPTOR silencing reduced protein expression of target protein (52%) in normoxia (Figure 11A). As shown in Figure 11B-C, phosphorylation of 4E-BP1
(Thr70) (+92%) and Akt (Ser473) (+74%) were significantly increased following
DEPTOR silencing. Treatment of cells with DEPTOR siRNA resulted in a significant
decrease in IGFBP-1 secretion (Figure 11D). Furthermore, DEPTOR silencing caused a
pronounced decrease in phosphorylation at the three serine sites Ser101, 119 and 169
(Figure 11E-G) with the decrease at Ser169 being slightly more prominent (Figure 11G).
Collectively, this data demonstrates that activation of mTOR signaling reduces both
IGFBP-1 secretion and phosphorylation in HepG2 cells.
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Figure 11. The effect of mTORC1 and mTORC2 activation via DEPTOR silencing
on IGFBP-1 secretion and phosphorylation
HepG2 cells were treated with scrambled or DEPTOR siRNA 72 hours (n=3 each).
A. A representative western blot of DEPTOR in HepG2 cell lysate from cells transfected
with scrambled or DEPTOR siRNA. Equal loading (30 µg protein) was performed.
DEPTOR siRNA silencing significantly decreased total DEPTOR protein expression. B.
A representative western blot of 4E-BP1 phosphorylation (Thr70) in HepG2 cell lysate
from cells transfected with scrambled or DEPTOR siRNA. Equal loading (20µg protein)
was

performed.

DEPTOR

silencing

significantly

increased

4E-BP1

(Thr70)

phosphorylation. C. A representative western blot of Akt phosphorylation (Ser473) in
HepG2 cell lysate from cells transfected with scrambled or DEPTOR siRNA. Equal
loading (30µg protein) was performed. DEPTOR silencing significantly increased Akt
phosphorylation (Ser473). D. A representative western blot of IGFBP-1 secretion in
HepG2 cell media from cells transfected with scrambled or DEPTOR siRNA. Equal
loading (aliquots of cell media) was performed. DEPTOR silencing caused a significant
decrease in IGFBP-1 secretion. E-G. Representative western blots of phosphorylated
IGFBP-1 at Ser101, 119, and 169 in HepG2 cell media from cells transfected with
scrambled or DEPTOR siRNA. Equal loading (aliquots of cell media) was performed.
DEPTOR silencing significantly decreased IGFBP-1 phosphorylation at Ser101, 119, and
169. Values are given as means + SEM. P <0.05 versus control; unpaired Student’s t test.
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Figure 11. The effect of mTORC1 and mTORC2 activation via DEPTOR silencing
on IGFBP-1 secretion and phosphorylation
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To further investigate the role of mTOR in inducing IGFBP-1 secretion and
phosphorylation in response to hypoxia, we silenced DEPTOR or raptor+rictor combined
in HepG2 cells. As determined by the protein expression of the targets (DEPTOR, raptor
or rictor), silencing efficiency was high in both normoxia and hypoxia (Figure 12A-C).
As shown in Figure 12D-E, in normoxic cells DEPTOR silencing activated both
mTORC1 and mTORC2 activity and raptor+rictor silencing caused a pronounced
decrease in mTORC1 and mTORC2 activity. Hypoxia alone markedly inhibited the
activity of mTORC1 and also of mTORC2 to similar levels. Importantly, activation of
mTOR in DEPTOR silenced cells prevented mTORC1 and C2 inhibition in response to
hypoxia. Furthermore, mTORC1 and C2 activity were reduced to a similar extent in
raptor+rictor silenced and in hypoxic cells, respectively.

As expected, hypoxia alone induced IGFBP-1 secretion. However, hypoxia failed to
induce IGFBP-1 secretion in DEPTOR silenced cells (Figure 12F). Moreover, in
raptor+rictor silenced cells hypoxia did not induce further secretion of IGFBP-1 than in
normoxic raptor+rictor silenced cells (+353%) (Figure 12F). Similarly, DEPTOR
silencing prevented the increase in IGFBP-1 phosphorylation at Ser101, 119 and 169 in
response to hypoxia (Figure 12G-I). Furthermore, hypoxia did not induce further IGFBP1 phosphorylation in cells with raptor+rictor silencing (+421%) (Figure 12G-I). Together,
these data provide evidence that IGFBP-1 secretion and phosphorylation in response to
hypoxia are mediated by inhibition of the mTORC1 and/or mTORC2 signaling pathway.
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Figure 12. The effect of mTORC1+mTORC2 inhibition and/or activation with and
without hypoxia on IGFBP-1 secretion and phosphorylation
HepG2 cells were treated with DEPTOR siRNA (to activate mTORC1+C2) or
raptor+rictor siRNA (to inhibit mTORC1+C2) for 48 hours, and then cells were
additionally cultured for 24 hours in normoxia (20% pO2) or in low oxygen (1% pO2,
hypoxia) (n=3 each).
A. A representative western blot of DEPTOR in HepG2 cell lysate from cells transfected
with scramble (normoxia), scramble (hypoxia), DEPTOR (normoxia), DEPTOR
(hypoxia), raptor+rictor (normoxia) and rictor +rictor (hypoxia) siRNA. Equal loading
(50 µg protein) was performed. DEPTOR siRNA significantly decreased total DEPTOR
protein expression, regardless of hypoxic status. B. A representative western blot of
raptor in HepG2 cell lysate from cells transfected with scramble (normoxia), scramble
(hypoxia), DEPTOR (normoxia), DEPTOR (hypoxia), raptor+rictor (normoxia) and
rictor+rictor (hypoxia) siRNA. Equal loading (50 µg protein) was performed. Raptor
siRNA silencing in cells decreased total raptor protein expression regardless of hypoxic
status. C. A representative western blot of rictor in HepG2 cell lysate from cells
transfected with scramble (normoxia), scramble (hypoxia), DEPTOR (normoxia),
DEPTOR (hypoxia), raptor+rictor (normoxia) and rictor+rictor (hypoxia) siRNA. Equal
loading (50 µg protein) was performed. Rictor siRNA silencing decreased total rictor
protein expression regardless of hypoxic status. D. A representative western blot of 4EBP1 phosphorylation (Thr70) phosphorylation in HepG2 cell lysate from cells transfected
with scramble (normoxia), scramble (hypoxia), DEPTOR (normoxia), DEPTOR
(hypoxia), raptor+rictor (normoxia) and rictor+rictor (hypoxia). Equal loading (20µg
protein) was performed. Hypoxia alone significantly inhibited 4E-BP1 (Thr70)
phosphorylation. When treated with DEPTOR siRNA, 4E-BP1 (Thr70) phosphorylation
was significantly increased regardless of hypoxic status, suggesting that DEPTOR knock
down prevented mTORC1 inhibition due to hypoxia alone. When treated with
raptor+rictor siRNA, 4E-BP1 phosphorylation was significantly inhibited regardless of
hypoxic status. E. A representative western blot of Akt phosphorylation (Ser473) in
HepG2 cell lysate from cells transfected with scramble (normoxia), scramble (hypoxia),
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DEPTOR (normoxia), DEPTOR (hypoxia) rictor+raptor (normoxia) and rictor+raptor
(hypoxia). Equal loading (30µg protein) was performed. Hypoxia alone significantly
inhibited Akt phosphorylation (Ser473). When treated with DEPTOR siRNA, Akt
phosphorylation (Ser473) was significantly increased compared to the control regardless
of hypoxic status, suggesting that DEPTOR knock down prevented mTORC2 inhibition
due to hypoxia alone. When treated with raptor+rictor siRNA, Akt phosphorylation
(Ser473) was significantly inhibited regardless of hypoxic status. F. A representative
western blot of IGFBP-1 secreted by HepG2 cells transfected with scramble (normoxia),
scramble (hypoxia), DEPTOR (normoxia), DEPTOR (hypoxia), raptor+rictor (normoxia)
and rictor+rictor (hypoxia) (n=3) using equal aliquots of cell media. Hypoxia alone
significantly increased IGFBP-1 secretion. When treated with DEPTOR siRNA, IGFBP1 secretion was not significantly different from control levels regardless of hypoxic
status, suggesting that constitutively activated mTOR signaling (due to DEPTOR
silencing) prevented the induction of IGFBP-1 secretion due to hypoxia. Conversely,
when treated with raptor+rictor siRNA, IGFBP-1 secretion was significantly increased to
levels similar to hypoxia alone, suggesting that hypoxia exerts it effects on IGFBP-1
secretion via mTORC1+C2 signaling. G-I. Representative western blots of IGFBP-1
phosphorylation at Ser101, 119, and 169 in cell media of cells transfected with scramble
(normoxia),

scramble

(hypoxia),

DEPTOR

(normoxia),

DEPTOR

(hypoxia),

raptor+rictor (normoxia) and rictor+rictor (hypoxia) (n=3) using equal aliquots of cell
media. Hypoxia alone significantly increased IGFBP-1 phosphorylation at Ser101, 119
and 169. When treated with DEPTOR siRNA, IGFBP-1 phosphorylation was
significantly reduced regardless of hypoxic status, suggesting that constitutively activated
mTOR signaling (due to DEPTOR siRNA silencing) prevented IGFBP-1 phosphorylation
as well as the induction of IGFBP-1 phosphorylation caused by hypoxia alone. When
treated with raptor+rictor siRNA, IGFBP-1 phosphorylation was significantly increased
to levels similar to hypoxia alone, suggesting that inhibition of mTOR during hypoxia is
responsible for the regulation of IGFBP-1 phosphorylation. Values are displayed as
mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.0001 versus control; One-way
analysis of variance; Dunnet’s Multiple Comparison Test; n=3.
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Figure 12. The effect of mTORC1+mTORC2 inhibition and/or activation
with and without hypoxia on IGFBP-1 secretion and phosphorylation
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3.11 Activation of mTORC1 signaling decreases IGFBP-1
secretion and phosphorylation
In order to investigate whether mTORC1 signaling specifically is involved in mediating
the effects of hypoxia on IGFBP-1, we next silenced the endogenous mTORC1 inhibitor
TSC2 to activate primarily mTORC1 in HepG2 cells. We validated silencing efficiency
of TSC2, and as shown in Figure 13A, total TSC2 protein expression was reduced (67%). Silencing of TSC2 led to significant increases in mTORC1 signaling alone as
determined by phosphorylation of 4E-BP1 at (Thr70) (+107%) (Figure 13B), while
mTORC2 signaling was not affected as assessed by the lack of change in phosphorylation
of Akt at (Ser473) (Figure 13C). Therefore these data confirmed that TSC2 silencing
results in increased mTORC1 activity without effecting mTORC2 activity in cells.
We then determined changes in IGFBP-1 secretion and phosphorylation as a result of
mTORC1 activation. TSC2 silencing resulted in a modest yet significant reduction in
IGFBP-1 secretion (-32%) (Figure 13D). Importantly, IGFBP-1 phosphorylation was
significantly reduced at all three serine residues (Ser119, 169, and 101) and the degree of
reduction was much more marked, (-70%) (Figure 13E-G) than the decreases in IGFBP-1
secretion. These data suggest that mTORC1 signaling is an important regulator of
IGFBP-1 phosphorylation.
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Figure 13. The effect of mTORC1 activation via TSC2 siRNA on IGFBP-1 secretion
and phosphorylation
HepG2 cells were treated with scrambled or TSC2 siRNA 72 hours (n=3 each).
A representative western blot of TSC2 in HepG2 cell lysate from cells transfected with
scrambled or TSC2 siRNA. Equal loading (30 µg protein) was performed. TSC2 siRNA
silencing of HepG2 cells significantly decreased total TSC2 protein expression. B. A
representative western blot of 4E-BP1 phosphorylation (Thr70) phosphorylation in
HepG2 cell lysate from cells transfected with scrambled or TSC2 siRNA. Equal loading
(20µg protein) was performed. TSC2 silencing significantly increased 4E-BP1 (Thr70)
phosphorylation. C. A representative western blot of Akt phosphorylation (Ser473) in
HepG2 cell lysate from cells transfected with scrambled or TSC2 siRNA. Equal loading
(30µg protein) was performed. TSC2 silencing did not affect Akt (Ser473)
phosphorylation. D. A representative western blot of IGFBP-1 secretion in HepG2 cell
media from cells transfected with scrambled or TSC2 siRNA. Equal aliquots of cell
media were loaded. TSC2 silencing caused a significant yet modest decrease in total
IGFBP-1 secretion. E-G. Representative western blots of IGFBP-1 phosphorylation at
Ser101, 119, and 169 in HepG2 cell media from cells transfected with scrambled or
TSC2 siRNA. Equal aliquots of cell media were loaded. TSC2 silencing caused a
significant decrease in IGFBP-1 phosphorylation at Ser101, 119, and 169. Values are
given as means + SEM. P <0.05 versus control; unpaired Student’s t test.

71

72

Figure 13. The effect of mTORC1 activation via TSC2 siRNA on IGFBP-1 secretion
and phosphorylation
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3.12 mTORC1 activation prevents the induction of IGFBP-1
secretion and phosphorylation in response to hypoxia
To further explore the role of mTORC1 in mediating the effect of hypoxia on IGFBP-1,
we studied the effects of hypoxia in cells with mTORC1 activation by TSC2 silencing. In
parallel we silenced raptor or rictor to inhibit mTORC1 and mTORC2 individually. As
shown in 14A-C, protein expression of TSC2, raptor and rictor were decreased following
corresponding siRNA silencing and the silencing efficiency was similar in hypoxic cells.

As expected, hypoxia inhibited mTORC1 and mTORC2 activity as evidenced by a
marked decrease in 4E-BP1 (Thr70) and Akt phosphorylation (Ser473) (Figure 14D-E)
and induced IGFBP-1 secretion (+180%) and phosphorylation at all three specific sites
(Ser101 +184%, 119 +188%, and 169 +235%), of which Ser 169 was most prominently
effected (Figure 14F-I). TSC2 silencing prevented mTORC1 inhibition caused by
hypoxia. mTORC2 on the other hand, was not affected by TSC2 or raptor siRNA but was
significantly inhibited due to hypoxia or rictor siRNA treatment (-75%). TSC2 silencing
prevented the increase in IGFBP-1 secretion in response to hypoxia (Figure 14F).
Similarly, mTORC1 activation decreased IGFBP-1 phosphorylation at all three sites and
prevented hypoxia-induced increases in phosphorylation (Figure 14G-I), indicating the
involvement of mTORC1 signaling. These data demonstrate that mTORC1 signaling
specifically regulates IGFBP-1 secretion and phosphorylation in response to hypoxia.
Furthermore, although phosphorylation at all three sites was altered, the Ser169 site was
more specific to mTORC1 in regulation of IGFBP-1 phosphorylation. Interestingly, rictor
silencing induced IGFBP-1 secretion, albeit to a relatively lesser extent, suggesting that
inhibition of either mTORC1 or C2 are able to drive IGFBP-1 secretion and
phosphorylation.
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Figure 14. The effect of individual mTORC1 activation and individual mTORC1
and mTORC2 inhibition with and without hypoxia on IGFBP-1 secretion and
phosphorylation
HepG2 cells were treated with TSC2 (to activate mTORC1), raptor (to inhibit mTORC1),
and rictor (to inhibit mTORC2) siRNA for 48 hours, and then cells were additionally
cultured for 24 hours in normoxia (20% pO2) or in low oxygen (1% pO2, hypoxia) (n=3
each).
A. A representative western blot of TSC2 in HepG2 cell lysate from cells transfected
with scramble (normoxia), scramble (hypoxia), TSC2 (normoxia), TSC2 (hypoxia),
raptor (normoxia), raptor (hypoxia), rictor (normoxia) and rictor (hypoxia) siRNA. Equal
loading (30 µg protein) was performed. TSC2 siRNA significantly decreased total TSC2
protein expression, regardless of hypoxic status. B. A representative western blot of
raptor in HepG2 cell lysate from cells transfected with scramble (normoxia), scramble
(hypoxia), TSC2 (normoxia), TSC2 (hypoxia), raptor (normoxia), raptor (hypoxia), rictor
(normoxia) and rictor (hypoxia) siRNA. Equal loading (50 µg protein) was performed.
Raptor siRNA significantly decreased total raptor protein expression, regardless of
hypoxic status. C. A representative western blot of rictor in HepG2 cell lysate from cells
transfected with scramble (normoxia), scramble (hypoxia), TSC2 (normoxia), TSC2
(hypoxia), raptor (normoxia), raptor (hypoxia), rictor (normoxia) and rictor (hypoxia)
siRNA. Equal loading (50 µg protein) was performed. Rictor siRNA significantly
decreased total rictor protein expression, regardless of hypoxic status. D. A representative
western blot of 4E-BP1 phosphorylation (Thr70) in HepG2 cell lysate from cells
transfected with scramble (normoxia), scramble (hypoxia), TSC2 (normoxia), TSC2
(hypoxia), raptor (normoxia), raptor (hypoxia), rictor (normoxia), and rictor (hypoxia)
siRNA (n=3). Equal loading (20µg protein) was performed. Hypoxia alone significantly
inhibited 4E-BP1 (Thr70) phosphorylation. When treated with TSC2 siRNA, 4E-BP1
phosphorylation was significantly increased from control levels regardless of hypoxic
status. Raptor siRNA significantly inhibited 4E-BP1 phosphorylation regardless of
hypoxic status. Rictor siRNA did not affect 4E-BP1 phosphorylation, but 4E-BP1
phosphorylation was significantly reduced in rictor siRNA+hypoxia treatment. E. A
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representative western blot of Akt phosphorylation (Ser473) in HepG2 cell lysate from
cells transfected with scramble (normoxia), scramble (hypoxia), TSC2 (normoxia), TSC2
(hypoxia), raptor (normoxia), raptor (hypoxia), rictor (normoxia), and rictor siRNA
(hypoxia) (n=3). Equal loading (30µg protein) was performed. Hypoxia alone
significantly inhibited Akt (Ser473) phosphorylation. TSC2 siRNA did not affect Akt
phosphorylation, although Akt phosphorylation was significantly reduced as a result of
hypoxia during TSC2 siRNA treatment. Similarly, raptor siRNA alone did not affect Akt
phosphorylation, but raptor siRNA+hypoxia treatment significantly reduced Akt
phosphorylation. Rictor siRNA significantly reduced Akt phosphorylation regardless of
hypoxic status. F. A representative western blot of IGFBP-1 secreted by HepG2 cells
transfected with scramble (normoxia), scramble (hypoxia), TSC2 (normoxia), TSC2
(hypoxia), raptor (normoxia), raptor (hypoxia), rictor (normoxia), and rictor siRNA
(hypoxia) (n=3) using equal aliquots of cell media. Hypoxia alone significantly increased
IGFBP-1 secretion. When treated with TSC2 siRNA, IGFBP-1 secretion was
significantly reduced from control levels regardless of hypoxic status, suggesting that
constitutively activated mTORC1 signaling (due to TSC2 silencing) prevented the
induction of IGFBP-1 secretion due to hypoxia. Conversely, when treated with raptor or
rictor siRNA, IGFBP-1 secretion was significantly increased to levels similar to hypoxia
alone, suggesting that hypoxia exerts it effects on IGFBP-1 secretion via mTORC1 or
combined mTORC1+C2 inhibition. G-I. Representative western blots of phosphorylated
IGFBP-1 (Ser101, 119, and 169) secreted by HepG2 cells transfected with scramble
(normoxia), scramble (hypoxia), TSC2 (normoxia), TSC2 (hypoxia), raptor (normoxia),
raptor (hypoxia), rictor (normoxia), and rictor siRNA (hypoxia) (n=3) using equal
aliquots of cell media. Hypoxia alone significantly increased IGFBP-1 phosphorylation.
When treated with TSC2 siRNA, IGFBP-1 phosphorylation was significantly reduced
from control levels regardless of hypoxic status at Ser101 and 169, and was also reduced
at Ser119 albeit not significantly, suggesting that constitutively activated mTORC1
signaling (due to TSC2 silencing) prevented the induction of IGFBP-1 phosphorylation
due to hypoxia. Conversely, when treated with raptor or rictor siRNA, IGFBP-1
phosphorylation was significantly increased to levels similar to hypoxia alone, suggesting
that hypoxia exerts it effects on IGFBP-1 phosphorylation via mTORC1 or combined
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mTORC1+C2 signaling. Values are displayed as mean + SEM. *p< 0.05, **p= 0.0010.05,

***p <

0.0001

versus

control;

Dunnet’s Multiple Comparison Test; n=3.

One-way

analysis

of

variance;
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Figure 14. The effect of individual mTORC1 activation and individual mTORC1
and mTORC2 inhibition with and without hypoxia on IGFBP-1 secretion and
phosphorylation
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4.0 Discussion

4

Key findings

Using HepG2 cells as a model for human fetal hepatocytes (96, 192-195) we have
identified a novel molecular mechanism by which mTOR regulates IGFBP-1 secretion
and phosphorylation in response to hypoxia. We demonstrate that mTORC1 or C2
inhibition increases whereas mTORC1 or C2 activation decreases IGFBP-1 secretion and
phosphorylation. Further, hypoxia failed to induce additional IGFBP-1 secretion in cells
with mTORC1 or C2 inhibition. Importantly, activation of mTORC1 or C2 prevented
IGFBP-1 secretion and phosphorylation in response to hypoxia. These findings suggest
that both mTORC1 and C2 signaling regulate IGFBP-1 secretion and phosphorylation in
a coordinated manner and that inhibition of either complex is sufficient to drive these
coordinated functional effects in hypoxia. We provide evidence that mTOR-mediated
IGFBP-1 phosphorylation in hypoxia reduces IGF-1R signaling and draw a link between
hypoxia-mediated mTOR inhibition and increased CK2 activity. Furthermore, we
demonstrate that IGFBP-1 phosphorylation was significantly increased at three serine
residues (Ser101, 119 and 169) in our treatments, of which phosphorylation at Ser169
was most prominent. Together this work proposes that increased IGFBP-1 secretion and
site-specific phosphorylation mediated by mTOR inhibition may contribute to restricted
fetal growth in response to hypoxia.

4.1 Mimicking fetal hypoxia in vitro
Phosphorylation increases the affinity of IGFBP-1 for IGF-I (202) and it is likely that
induction of IGFBP-1 phosphorylation in hypoxia is a powerful mechanism for the
regulation IGF bioavailability in the modulation of fetal growth. This assumption was
supported by our previous in vitro data demonstrating that hypoxia resulted in increased
phosphorylation of IGFBP-1 which increased its binding affinity to IGF-I 300-fold and
markedly inhibited IGF-I-stimulated cell growth (192). The use of 1% O2 in vitro to
represent the in vivo hypoxic state has been well established (172, 192, 203). Low oxygen
tension, which is usually defined as hypoxia in vitro, has been established in many tissues
with an average of 3% O2 (204-206), and has been shown to reach as low as 1-2% in the
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descending aorta within hypoxic fetal lambs (207) compared to healthy oxygen levels
which range from 4% O2 in muscles to 12.1% O2 in the kidney (208). 1% O2 due to low
oxygen tension has further been detected in bone marrow, thymus, and the kidney
medulla (209). Using atmospheric air (20% O2) in vitro to represent normoxia in vivo is
also commonly used (106, 172, 192, 203), and is usually referred to as normoxia although
it may be a state of hyperoxia. Subsequently, we used 1% O2 (hypoxia) and 20% O2
(normoxia) in our in vitro studies in this dissertation as in our previous work (192, 203).

Studies on the role of IGFBP-1 phosphorylation and the mechanisms regulating hypoxiainduced IGFBP-1 phosphorylation in the development of FGR are limited. However, we
recently provided evidence that IGFBP-1 is hyperphosphorylated in human FGR (96).
We also established a causative link between IGFBP-1 hyperphosphorylation and mTOR
inhibition in a baboon model of FGR in vivo (96). Furthermore, we conducted
mechanistic studies using HepG2 cells and validated the use of our HepG2 cell culture
model using primary fetal hepatocytes (96). Using this as the basis, the mechanistic data
in this current study was generated using HepG2 cells. HepG2 cells are human liver
carcinoma cells that demonstrate biotransformation characteristics and the gene
expression patterns similar to primary human fetal hepatocytes (194, 195). Thereby using
HepG2 cells in this study we have now established a novel mTOR mediated mechanism
linking hypoxia to increased IGFBP-1 phosphorylation that also inhibited IGF-I function.

4.2 Regulation of IGFBP-1 in hypoxia
Elevated IGFBP-1, resulting in decreased bioavailability of IGF-I, has been proposed to
be an important mechanism restricting fetal growth in both human FGR and in animal
models of chronic intrauterine hypoxia (104, 210-213). Hypoxia up-regulates IGFBP-1
mRNA and protein expression in HepG2 cells and human fetal hepatocytes in vitro (106),
as well in zebra fish in vivo (104). Previous studies on the role of IGFBP-1 in the
regulation of fetal growth have mainly focused on the mechanisms that determine
induction of IGFBP-1 gene transcription and expression. Regulation of gene transcription
by hypoxia involves binding of the transcription factor HIF-1α to a HRE which has been
identified in the IGFBP-1 gene (106). mTORC1 promotes the expression of HIF-1α by
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regulating the translation of the α subunit of HIF which activates the transcription of
several genes responsive to hypoxia such as Glut1, Pfkp, and Pdk1 (214). Furthermore, a
role for HIF1 has been implicated in IGFBP-1 gene expression (106). Thus, there is an
indirect indication for a role of mTOR signaling in linking hypoxia to the expression of
IGFBP-1 in fetal hepatocytes. The mechanisms modulating IGFBP-1 phosphorylation
and implications of mTOR signaling in changes to IGFBP-1 phosphorylation in response
to hypoxia have received much less attention. Thus, the post-translational effects of
IGFBP-1 phosphorylation due to hypoxia were investigated in this study.

4.3 The functional significance of IGFBP-1 phosphorylation
on IGF-I signaling
The ability of hypoxia-induced IGFBP-1 phosphorylation to modulate IGF function due
to mTOR inhibition was tested through our IGF-I induced IGF-1R autophosphorylation
assay. The bioassay utilizing P6 cells (IGF-1R overexpressing BALB/c3T3 derivative)
(126) in our current study was a direct adaptation of the previously established assay
system using NIH-3T3 cells (215, 216). Here, we demonstrate the ability of recombinant
human IGF-I to stimulate human IGF-1R expressed by P6 cells. Unstimulated
BALB/3T3 cells contain approximately 8000 IGF-1 receptors per cell, whereas P6 cells
transfected with human IGF-1R cDNA contain upwards of 43000 receptors, making them
highly sensitive to induction by IGF-I (217).
IGF-1R is a transmembrane receptor tyrosine kinase which is responsible for the
mediation of IGF-I action. It has a high binding affinity towards IGF-I and IGF-II, and
thus functions to facilitate IGF signaling (72). Upon ligand binding to IGF-1R, the
receptor kinase is activated and IGF-1R tyrosine autophosphorylation, as well as
downstream substrate tyrosine phosphorylation occur (60). This process leads to
enhanced cellular proliferation and protein synthesis as well as the inhibition of apoptosis
(218). IGF-1R is a tertameric protein which consists of 2 extracellular α-subunits that are
disulphide-bound to each other and to 2 β-subunits which span the cell membrane and
also contain a cytoplasmic portion (219). The β-subunits contain the kinase activity of
IGF-1R, thus providing a rationale for our analysis of IGF-1Rβ phosphorylation only
(220). The assessment of Tyr1135 phosphorylation as a representation of IGF-1R
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activation has been well established (96, 126, 221, 222). The activation loop of IGF-1R is
a flexible portion of the C-lobe of the kinase domain (223). In the unactivated state of
IGF-1R, the activation loop forms an autoinhibitory conformation in which Tyr1135 is
bound to the active site. This prevents Tyr1135 phosphorylation in the absence of IGF-1R
ligand binding (223). IGF-I binding to IGF-1Rα induces IGF-1Rβ autophosphorylation
which occurs in trans (one IGF-1Rβ kinase domain phosphorylating the other), and three
tyrosine residues of IGF-1Rβ are phosphorylated by the process – Tyr1131, Tyr1135, and
Tyr1136 (224). Although Tyr1131 and Tyr1136 are also phosphorylated by the event,
studies have demonstrated that Tyr1135 is the first residue to be phosphorylated and in
general is the most predominant phospho-site involved in IGF-1R activation (223).
Furthermore, only Tyr1135 has been characterized to be bound in the active site during
the autoinhibitory conformation (223). These data support our use of assessing Tyr1135
phosphorylation as a means to determine IGF-1R activation due to IGF-I ligand binding.
Our data demonstrates that IGF-I-mediated IGF-1R activation is reduced in the presence
of HepG2 cell media, suggesting that IGFBP-1 was able to reduce interactions between
IGF-I and IGF-1R.

Through densitometric analysis of IGFBP-1 secretion from our rapamycin, hypoxia, and
rapamycin+hypoxia treatment, we were able to quantify levels of total IGFBP-1 present
in the conditioned medias. This allowed us to use aliquots of conditioned HepG2 cell
media which were normalized to contain equal total IGFBP-1. As the induction of
IGFBP-1 phosphorylation was proportionately higher than secretion in treated HepG2
cell media, our resultant media aliquots contained equal total IGFBP-1, but differing
degrees of phosphorylated IGFBP-1 - namely increased phosphorylation in the treated
HepG2 cell media aliquots. Importantly, mixtures of treated HepG2 cell media containing
a proportionately higher quantity of phosphorylated IGFBP-1 (from treated HepG2 cells)
along with human recombinant IGF-I were able to reduce the degree of IGF-1R
autophosphorylation to a greater extent compared to the untreated HepG2 cell media,
reinforcing the notion that rapamycin and/or hypoxia-induced phosphorylated IGFBP-1
from HepG2 cells was able to yield a greater inhibitory effect on IGF-I-mediated IGF-1R
signaling. It is possible that secreted IGFBP-3 may interfere with IGF-I sequestration.
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However, the use of equal concentration of total IGFBP-1 exposed to free IGF-I in
control and treated samples suggests that increased interactions between IGFBP-1 and
IGF-I were driven by IGFBP-1 phosphorylation, functioning to increase IGF-I
sequestration and decrease IGF-1R signaling. This is supported by evidence showing that
HepG2 cells secrete and IGFBP-3 in negligible quantities compared to the
overabundance of IGFBP-1 secretion (203), and our previous studies showed that
mutating key IGFBP-1 phospho-sites to alanine strongly reduced the binding affinity of
IGFBP-1 to IGF-I (126). Here, we furthered these findings by showing that both mTOR
inhibition by rapamycin and hypoxia functionally altered the degree of IGF-1R signaling
observed, and that combined treatment did not further inhibit IGF-1R signaling,
reinforcing the concept that hypoxia-induced IGFBP-1 phosphorylation is mediated
through mTOR inhibition.

4.4 HepG2 cell viability is unaltered by rapamycin and
hypoxic treatments
Although our rapamycin and hypoxia treatments resulted in increased IGFBP-1 secretion
and phosphorylation, we tested the viability of cells post-treatment to ensure that the
degree of induction seen was valid and not altered due to increased cell death via the
Trypan Blue exclusion assay. Trypan blue is a diazo dye which is commonly used in
microscopy for cell counting and tissue viability (225). It can allow for effective
distinguishing of live versus dead cells by exploiting the high selectivity of live cell
membranes. As cells must be highly selective regarding which compounds can pass
through the cell membrane, foreign compounds such as trypan blue can be used to stain
cells. Live cells will exclude the absorption of trypan blue, whereas dead cells will be
stained blue throughout (225). We were able to utilize this technique using an automated
cell counter to yield high-throughput results and effectively quantify a large number of
cells for viability. Our results show that none of the rapamycin, hypoxia, or combined
rapamycin+hypoxia treatments altered cell viability, demonstrating that the induction of
IGFBP-1 secretion and phosphorylation quantified due to our treatments was accurate
and not affected by cell death.
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4.5 The involvement of CK2 in hypoxia-induced IGFBP-1
phosphorylation
The molecular mechanisms upstream or downstream of mTOR which ultimately induce
IGFBP-1 secretion and phosphorylation are unknown. Although in our recent study we
have provided clear evidence for a key role of CK2 in IGFBP-1 phosphorylation (96),
whether CK2 directly phosphorylates IGFBP-1 is currently unknown. CK2 is a well
established serine/threonine protein kinase which is classified to function in a messengerindependent manner, as its activity is not dependent on small molecules which are
typically involved in second messenger kinase regulation (226). CK2 functions in a
tetrameric complex composed of CK2α and CK2α’ catalytic subunits as well as two
CK2β regulatory subunits (227, 228). Variance in the subunits has been characterized
between different organisms. The presence of both CK2α and CK2α’ catalytic subunits
are well documented in humans (227, 228). However, various mammalian systems have
been shown to contain either two CK2α or two CK2α’ catalytic subunits (229). Further,
in humans, only one CK2β regulatory subunit has been identified, whereas in
Saccharomyces cerevisiae multiple forms of CK2β have been established (230). We
previously chose to investigate CK2 as a potential kinase for IGFBP-1 due to the
identification of a consensus sequence within IGFBP-1 for phosphorylation by CK2
(191).

The regulation of CK2 under various conditions of cellular stress seems to occur in a celland tissue-type specific manner (96). We have previously demonstrated that CK2 subunit
expression is increased in an in vivo maternal nutrient restriction model using baboon
fetal liver (96). In these cells, CK2 activity was also increased. Interestingly, mTOR
inhibition via rapamycin treatment increased CK2 activity in HepG2 cells, but not
expression of the CK2 subunits (96). This suggests that mTOR inhibition regulates CK2
activity, but not at the transcriptional or translational levels in HepG2 cells. Further,
silencing of CK2 via siRNA resulted in significantly decreased IGFBP-1 phosphorylation
in HepG2 cells, reinforcing the involvement of CK2 in IGFBP-1 phosphorylation (96).
Here, we were able to replicate these results with rapamycin treatment on HepG2 cells,
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where CK2 subunit expression was not altered but activity was increased. Interestingly,
we have now demonstrated very similar results with hypoxic treatment as well as
combined rapamycin+hypoxia treatment. In these treatments, CK2 subunit protein
expression was not significantly different from control cells, although a trend of
reduction in CK2α and CK2β subunit expression due to hypoxia was observed. However,
these treatments did significantly induce CK2 activity to very similar levels as rapamycin
treatment, further demonstrating mTOR inhibition as a mediatory step in hypoxiainduced IGFBP-1 phosphorylation which involves the activity of CK2. It seems likely
that inhibition of mTOR in hypoxia activates CK2 which in turn phosphorylates IGFBP-1
either directly or through intermediate mechanisms which currently remain unknown. As
mTOR is a kinase, we postulate that mTOR inhibition activates CK2 through inhibition
of phosphatase activity, in which mTOR inhibition results in the downregulation of an
unidentified phosphatase which otherwise prevents phosphorylation-mediated CK2
activation (190). In this way, inhibition of a kinase (mTOR) can plausibly result in the
activation of another kinase. Identification of this interaction remains to be investigated.
IGFBP-1 is readily secreted out of the cell due to a signal peptide sequence for secretion
in the IGFBP-1 precursor peptide (81), suggesting that protein maturation and
phosphorylation occur in a localized manner near the cell membrane. Interestingly,
numerous studies have reported localized CK2 activity at the cell membrane (231-234),
providing indirect evidence for CK2-mediated IGFBP-1 phosphorylation.

4.6 The roles of TSC2 and DEPTOR in mTOR regulation
during hypoxia
DEPTOR is a naturally occurring inhibitor of mTOR signaling and directly binds to
mTORC1 and mTORC2 and inhibits mTOR activity (235). Reduced DEPTOR
expression has been shown to increase 4E-BP1 (Thr70) (149) and S6K (Thr389), as well
as Akt (Ser473) phosphorylation (236) – phospho-sites directly phosphorylated by
mTORC1 and mTORC2, respectively, and thus constitutively activates the functions of
both mTORC1 and mTORC2 (236). Indeed, our data demonstrates that there is a basal
DEPTOR-mediated inhibition of both mTORC1 and mTORC2 signaling in HepG2 cells.
Similarly, activation of mTORC1 individually has been achieved by silencing TSC2, a
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negative regulator of mTORC1 (237) and by silencing TSC2 alone we were able to
activate mTORC1 in our current studies.
mTORC1 inhibition by TSC2 occurs upstream of mTOR, and the effects are indirect. The
TSC1/2 complex acts as a negative regulator of mTORC1 by activating the GTPase
activity of protein Rheb (187, 188). TSC2 specifically contains a GTPase activating
protein (GAP) domain which, when stabilized by TSC1, facilitates the conversion of
RhebGTP to RhebGDP (188). The presence of RhebGDP does not have an effect on
mTORC1 signaling. However, cellular accumulation of RhebGTP is a potent activator of
mTORC1 activity (187, 188). We demonstrate in this study that siRNA-mediated
silencing of TSC2 was able to activate mTORC1 signaling with no effect on mTORC2
signaling, which presumably occurred through the accumulation of RhebGTP.
Furthermore, it is known that hypoxia functions to reduce mTORC1 signaling though this
pathway. Hypoxic conditions result in the activation of the activation of HIF-1α,
activating protein REDD1 which then induces TSC1/2 activity (186). Thus, silencing of
TSC2 was able to prevent the effects of hypoxia on mTORC1 signaling.

Interestingly, hypoxic effects on mTORC1 and mTORC2 signaling were also attenuated
through DEPTOR silencing. It has been shown that DEPTOR binds directly to both
mTORC1 and mTORC2 (144), and that silencing of DEPTOR results in the activation of
both mTORC1 and mTORC2 signaling (150). This direct interaction between DEPTOR
and both mTOR complexes has been implicated as a form of basal inhibition for mTOR
signaling (150). Here we have demonstrated that alleviation of this interaction was able to
increase both mTORC1 and mTORC2 activity in hypoxia. This reinforces the concept
that mTOR signaling can be altered through multiple pathways, and that hypoxiamediated TSC1/2 activation was not able to effect mTOR signaling as the alleviation of
direct DEPTOR:mTOR interaction resulted in increased mTOR signaling regardless of
oxygen status. DEPTOR silencing activated mTORC1 and mTORC2, which reduced
IGFBP-1 secretion/phosphorylation and prevented the IGFBP-1 response to hypoxia.
These findings are consistent with the possibility that both mTORC1 and mTORC2 are
involved in mediating the effect of hypoxia on IGFBP-1 secretion and phosphorylation.
Using silencing of TSC2, which specifically activates mTORC1, we confirmed that
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mTORC1 activation is sufficient to reduce IGFBP-1 secretion and phosphorylation and
prevent the effects of hypoxia on IGFBP-1.

4.7 mTOR signaling and hypoxia-induced IGFBP-1
phosphorylation
It is well-established that mTORC1 signaling is inhibited by hypoxia (172, 173), whereas
the effects of hypoxia on mTORC2 have not been well characterized. Previous studies
have generated inconsistent results, reporting both increased and decreased mTORC2
activity in response to hypoxia in different cells (189). In agreement with previous
literature, our data shows that mTORC1 and mTORC2 activity are decreased due to
hypoxia in HepG2 cells (189). To determine the specific roles of the two mTOR
complexes in regulating IGFBP-1 secretion and phosphorylation during hypoxia, we
utilized systematic mTOR inhibition and activation strategies in combination with
hypoxia.

Constitutive inhibition of mTORC1 and mTORC2 via raptor and rictor siRNA,
respectively, induced both IGFBP-1 secretion and phosphorylation, which was not
enhanced further by hypoxia. This suggests that mTOR inhibition in hypoxia is
responsible for the induction of IGFBP-1. As the siRNA treatment occurred for 72 hours,
with only the last 24 hours with and without hypoxia, an additive effect in IGFBP-1
induction would be expected if hypoxia was driving IGFBP-1 secretion/phosphorylation
through a molecular pathway unrelated to mTOR signaling. We have shown here that
constitutive mTOR inhibition is able to drive IGFBP-1 induction, and that the subsequent
addition of hypoxia did not further enhance levels of IGFBP-1. Interestingly, cells
exposed to scrambled siRNA with the last 24 hours of the 72 hour incubation in hypoxia
resulted in levels of total and phosphorylated IGFBP-1 which were similar to cells
exposed to raptor and rictor siRNA in normoxia for 72 hours. This suggests that siRNA
treatment operates in a temporal manner, in which constitutive mTOR inhibition was
more potent within approximately the last 24 hours of treatment. This is in agreement
with the literature, in which 72 hour siRNA transfection periods in order to yield optimal
effects of the treatment are common (238-240). Further, constitutive inhibition of either
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complex due to individual raptor or rictor siRNA were both able to induce IGFBP-1
secretion and phosphorylation to similar levels as hypoxia alone, with raptor silencing
resulting in slightly higher induction than rictor silencing. Again, these effects were not
augmented by hypoxia, suggesting that constitutive inhibition of mTORC1 or mTORC2
are sufficient to drive IGFBP-1 secretion and phosphorylation. This suggests that both
mTORC1 and mTORC2 may function in a coordinated manner to regulate IGFBP-1.

Conversely, constitutive mTORC1 and mTORC2 activation via DEPTOR silencing
reduced both IGFBP-1 secretion and phosphorylation suggesting that basal levels of
mTOR signaling regulate IGFBP-1 under untreated conditions, and that increased mTOR
activity due to alleviation of endogenous basal mTOR inhibition reduces IGFBP-1
secretion and phosphorylation to below basal levels. This relief of basal inhibition
resulted in increased mTOR activity which remained consistent in hypoxia, and the
sustained and elevated mTOR signaling activity in hypoxia was able to prevent hypoxiainduced IGFBP-1 secretion and phosphorylation. This strongly implicates the inhibition
of mTOR signaling in the regulation of hypoxia-induced IGFBP-1 secretion and
phosphorylation in HepG2 cells.

We also investigated the effect of constitutive mTORC1 signaling via silencing of TSC2.
TSC2 silencing alone caused a modest reduction in IGFBP-1 secretion, but a larger
reduction in IGFBP-1 phosphorylation. As previously discussed, the TSC1/2 pathway is
responsible for incorporating cellular responses to hypoxia with mTORC1 signaling.
When TSC2 silencing was performed, resulting in constitutive mTORC1 activation in
combination with hypoxia, both IGFBP-1 secretion and phosphorylation induction due to
hypoxia were prevented. This data suggests that even though constitutive inhibition of
mTORC1 or mTORC2 signaling were able to induce IGFBP-1 to similar levels as
hypoxia alone, the inhibition of mTORC1 specifically due to hypoxia is responsible for
hypoxic regulation of IGFBP-1. This is consistent the possibility that induction of
IGFBP-1 and subsequent reduction in IGF-I bioavailability can be mediated by signaling
events which only affect one mTOR complex, representing a wide array of possible
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mechanisms by which IGFBP-1 secretion and phosphorylation, and therefore IGF-I
bioavailability and fetal growth, can be regulated.

4.8 IGFBP-1 phosphorylation at specific residues due to
hypoxia
It is known that IGFBP-1 is phosphorylated at multiple (five serine) sites (123, 128, 192,
196, 197, 202, 241). We have earlier demonstrated that IGFBP-1 phosphorylation at three
specific serine residues (Ser101, 119 and 169) was increased in amniotic fluid (196, 241)
and umbilical cord plasma of human FGR babies as well as in fetal liver and cord plasma
from our baboon model of maternal nutrient restriction which results in FGR (96). In
FGR, reductions in nutrient and oxygen delivery are the most common challenges to the
developing fetus. Interestingly, in our previous study using HepG2 cells we have
demonstrated significant induction of IGFBP-1 phosphorylation at all three sites (Ser101,
119 and 169) examined in hypoxia and leucine deprivation (192). Furthermore, using
mass spectrometry (192) we earlier showed that although Ser101 was a common site, two
distinct patterns of IGFBP-1 phosphorylation were detected between the two stimuli:
hypoxia caused IGFBP-1 hyperphosphorylation at Ser98 and 169 while leucine
deprivation at Ser119 which concomitantly led to 300- and 30-fold increases in IGF-I
affinity, respectively (192). The data from the current study demonstrated a similar
pattern of increases in IGFBP-1 phosphorylation at Ser101, 119 and 169. This suggests
that site-specific phosphorylation of IGFBP-1 under conditions of cellular stress occurs in
order to modulate the affinity of IGFBP-1 to IGF-I, potentially providing increased
control over the bioavailability of IGF-I for IGF-I-mediated growth in FGR. Although
Ser98 phosphorylation is considered to be highly significant in combination with Ser169
in increasing binding affinity of IGFBP-1 for IGF-I and reducing IGF-I bioavailability, as
suggested by our previous study (129), it could not be tested due to a lack of available
antibody. Furthermore, it is also possible that additional novel sites may be involved in
phosphorylation during mTOR inhibition and/or hypoxia for which further studies would
need to be conducted.
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4.9 Future studies
Investigating the role of CK2 in hypoxia-induced IGFBP-1 phosphorylation
Although data from this study implicates mTOR signaling in the regulation of hypoxiainduced IGFBP-1 secretion and phosphorylation, numerous aspects of this regulatory
system remain to be elucidated. Our recent data implicates protein kinase CK2 in the
regulation of IGFBP-1 downstream of mTOR (96). Previous work in our lab with 4,5,6,7tetrabromobenzotriazole (TBB), a chemical inhibitor of CK2, has shown that
phosphorylation of IGFBP-1 is attenuated when TBB is combined with rapamycin (96).
This demonstrates the role of CK2 in mTOR-inhibition mediated IGFBP-1
phosphorylation. Combining CK2 inhibitor TBB or CK2 siRNA with hypoxia would lead
to a greater understanding of the specific role of CK2 in hypoxic regulation of IGFBP-1.
It would be expected that hypoxia induces IGFBP-1 secretion and phosphorylation, and
that silencing or inhibiting of CK2 in combination with hypoxia may prevent IGFBP-1
secretion and phosphorylation. Another possibility would be probe for direct
CK2:IGFBP-1 interaction via the utilization of immunofluorescence mircoscopy to test
for co-localization between CK2 and IGFBP-1, as well as co-immunoprecipitation, GST
pull-down assays, or fluorescence resonance energy transfer (FRET) binding assays with
recombinant CK2 and IGFBP-1. These experiments would allow us to determine if
intermediary processes occur between CK2 activation and IGFBP-1 secretion and
phosphorylation or if CK2 directly phosphorylates IGFBP-1.

Investigating the in vivo role of IGFBP-1 phosphorylation in regulation of
fetal growth in hypoxia
Previously, an in vivo study using chick embryos demonstrated that both hypoxia and
nutrient deprivation were associated with FGR; however prenatal hypoxia and
undernutrition may have differential effects on fetal development (238). As previous
work in the literature has demonstrated an in vivo link between hypoxia and FGR in
chicken embryos (25), investigating the effects of hypoxia on IGFBP-1 secretion and
phosphorylation in chicken embryos in vivo would be a logical progression of our studies.
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This would allow us to effectively compare site-specific IGFBP-1 phosphorylation and
IGF-I actions between our in vitro model and fetal hypoxia in vivo. Phosphorylation may
be induced at the same or even different sites compared to humans, but importantly it
would be expected that IGFBP-1 phosphorylation would increase its affinity to and
reduce the actions of IGF-I. In vivo chicken embryo hypoxia +/- experiments could be
followed up with detailed mechanistic studies. The use of morpholino injection to target
and silence mTOR components raptor and rictor in chicken embryos with and without
hypoxia would allow us to investigate the role of mTOR in the hypoxic regulation of
IGFBP-1 in vivo. The overall effects on fetal growth could be tested via tissue-specific
and entire organism wet weights measurement, in order to validate chicken embryos as a
model for hypoxia-induced FGR and to investigate the effects of our treatments on fetal
growth in vivo.

Development of therapeutic strategies
Through in vitro studies, it may be possible to investigate the potential development of
therapeutic small molecule inhibitors aimed at increasing levels of IGF-I signaling. For
example, a small molecule which could bind to Cys38 of IGFBP-1 may be able to
prevent IGF-I:IGFBP-1 binding, resulting in increased fetal growth. This is supported by
evidence showing that mutation of Cys38 of IGFBP-1 abolished IGF-I binding (89).
Another target residue on IGFBP-1 which binding of a small molecule inhibitor may
prove beneficial is Ser169, as we have shown that phosphorylation of Ser169 occurs
during hypoxia, and hypoxia-induced IGFBP-1 phosphorylation binds to IGF-I with
markedly higher affinity (192). Initial proof of principle studies would need to be
conducted, likely through IGF-I bioavailability assays as performed in this study and
IGFBP-1:IGF-I binding affinity assays.
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4.10 General summary
Together we have demonstrated a novel molecular link between the mTOR and IGF
signaling axes, providing compelling evidence that hypoxia-induced IGFBP-1 secretion
and site-specific phosphorylation occurs through the inhibition of mTORC1 signaling.
We also demonstrate that that prolonged inhibition of mTORC2 signaling is able to drive
IGFBP-1 secretion and phosphorylation. Further, we have established that mTORmediated hypoxia-induced IGFBP-1 phosphorylation is linked with increased CK2
activity, and is functionally significant because these changes caused a marked decrease
in IGF-I bioavailability. Thus, our data provide a mechanistic link between fetal hypoxia
and reduced IGF-I signaling via mTOR-inhibition-mediated increases in IGFBP-1
secretion and site specific phosphorylation (Figure 15). These pathways may contribute
to restricted fetal growth in response to hypoxia in vivo.
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Figure 15. Proposed model linking hypoxia to IGFBP-1
Inhibition of mTOR signaling (resulting in an increase in CK2 activity) is a key
molecular link between hypoxia, increased IGFBP-1 secretion and phosphorylation, and
reduced IGF-I bioavailability in FGR (96).

Figure 15. Proposed model linking hypoxia to IGFBP-1
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4.11 Limitations
Although we were able to determine site-specific phosphorylation of IGFBP-1 due to
hypoxia, we were not able to investigate the effects of our treatments on other
phosphorylation sites of IGFBP-1, namely Ser95 and Ser98, or novel phosphorylation
sites. This was due to the lack of available phospho-site specific antibodies. Determining
if phosphorylation at Ser95 and 98 as well as other novel sites was increased due to our
treatments would have been an intriguing possibility that would have allowed us to
determine if IGFBP-1 is preferentially phosphorylated in the linker and/or C terminal
regions due to hypoxia. These possibilities are under investigation by the use of mass
spectrometry.
Further, we speculate that IGFBP-1 phosphorylation increases its affinity towards IGF-I
through synergistic interactions of its phospho-sites. This synergism likely involves novel
phosphorylation sites, as well as the previously established Ser95 and 98 phospho-sites.
The investigation into this potential synergism through the use of site-directed
mutagenesis of various combinations of phosphorylation sites would have provided
compelling evidence of this synergism.
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Appendices
Appendix A: Supplementary figures, data, and permissions to use copyrighted
material
Figure A1. Broad perspective of mTOR signaling
Schematic showing a thorough list of mTORC1 and mTORC2 interactions,
demonstrating the complexity of mTOR signaling and its many roles in the cell (137).
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Figure A2. The effect of rapamycin and/or hypoxia treatment on albumin secretion
HepG2 cells were cultured for 24 hours in normoxia (20% pO2) or in low oxygen (1%
pO2, hypoxia) with and without rapamycin (100 nM) (n=3 each).
A representative western blots of secreted albumin in cell media of control, rapamycin,
hypoxia and rapamycin+hypoxia treated HepG2 cells (n=3 each) using equal aliquots of
cell media. Rapamycin, hypoxia, and combined rapamycin+hypoxia all modestly yet
significantly reduced albumin secretion. Values are displayed as mean + SEM. *p< 0.05,
**p= 0.001-0.05, ***p < 0.0001 versus control; One-way analysis of variance;
Dunnet’s Multiple Comparison Test; n=3.
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Figure A3. The effect of rapamycin and hypoxia on HepG2 cell viability.
Summary of HepG2 cell viability after 24 hours of rapamycin, hypoxia, or
rapamycin+hypoxia treatments. Cell viability was assessed using equal aliquots of cell
suspension (10 µl) via the Trypan Blue exclusion assay. Cell viability was determined as
a measure of live/total cells. Rapamycin, hypoxia, and rapamycin+hypoxia treatments all
demonstrated nearly identical cell viability to control cells. Values are displayed as
mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.0001 versus control; One-way
analysis of variance; Dunnet’s Multiple Comparison Test; n=3.
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Figure A4. Copyright permission for Figure 1B.
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Figure A5. Copyright permission for Figure 2B.
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Figure A6. Copyright permission for Figure 15.
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Abstract
Impaired oxygen and nutrient delivery to the fetus result in fetal growth restriction
(FGR). IGF-I is a key regulator of fetal growth and IGF-I bioavailability is determined by
IGFBP-1, which binds IGF-I and inhibits its signaling. Hypoxia induces IGFBP-1
hyperphosphorylation resulting in decreased IGF-I bioavailability. We recently
established a link between inhibition of mechanistic target of rapamycin (mTOR) and
IGFBP-1 hyperphosphorylation. Here, we tested the hypothesis that IGFBP-1
hyperphosphorylation in hypoxia is mediated by mTOR inhibition. Using HepG2 cells,
we inhibited mTOR signaling either by rapamycin or siRNA targeting raptor (mTORC1)
and/or rictor (mTORC2) in hypoxia (1% O2) or normoxia (20% O2). Conversely, we
activated mTORC1 or mTORC1+mTORC2 by silencing endogenous mTOR inhibitors
(TSC2/DEPTOR) in hypoxia or normoxia. Western blotting was used to assess IGFBP-1
secretion/phosphorylation and the effects of IGFBP-1 phosphorylation on IGF-I
bioavailability using IGF-1R autophosphorylation. Using phospho-site specific IGFBP-1
antibodies we demonstrated that hypoxia or inhibition of either mTORC1 and/or
mTORC2 induced similar degrees of IGFBP-1 secretion and phosphorylation at
Ser101/119, and 169, which markedly reduced IGF-1R autophosphorylation. Activation
of mTORC1+C2 by DEPTOR silencing or activation of mTORC1 by silencing TSC2
reduced

IGFBP-1

secretion/phosphorylation

and

prevented

IGFBP-1

hyperphosphorylation in response to hypoxia.
Multiple Reaction Monitoring Mass Spectrometry (MRM/MS) quantitatively validated
IGFBP-1 hyperphosphorylation at Ser101/119, and 169. MRM MS analysis further
showed increased phosphorylation at Ser98 and at a novel residue Ser174 which was
sensitive to mTOR inhibition. Structural modeling indicated that rapamycin-sensitive
phospho Ser174 being in close proximity to IGF-I binding site may directly influence
IGF-I affinity. Together, this study demonstrates that signaling through either the
mTORC1 or mTORC2 pathway is sufficient to induce site-specific hyperphosphorylation
of IGFBP-1 in response to hypoxia. These data put forward a novel mechanistic link

130

between hypoxia, IGFBP-1 hyperphosphorylation and decreased IGF-I bioavailability
mediated by inhibition of mTOR which may contribute to restricted fetal growth in
response to hypoxia.

